Patent Application
20080200976
The present invention relates to a stent having a supporting structure of a non-particulate inorganic carbon material.
Implants are widely used as short-term or long-term devices to be implanted into the human body in different fields of application, such as orthopedic, cardiovascular or surgical reconstructive treatments. The ongoing development of medical devices including long term implants, such as articular and intravascular prostheses, and short term implants like catheters, has improved the efficacy of surgical and/or interventional treatments. However, the introduction of a ‘foreign’ material into a living organism can cause adverse reactions, such as thrombus formation or inflammation. This is generally due to biochemical reactions at the interface between the implant and the patient's body. Prior art materials comprise significant drawbacks in terms of biocompatibility or functionality or efficacy. Significant drawbacks of prior art solutions are related either to biocompatibility of materials, suitability of the used materials for implant design, inability to provide controlled porosities and pore sizes and/or reduced usability to provide and release beneficial agents like drugs.
Different biodegradable and non-degradable implants may be developed for implantation into body passageways to maintain the patency through the passageways Such passageways that can be treated for maintaining the patency are for example coronary arteries, peripheral arteries, veins, biliary passageways, the tracheal or bronchial passageways, prostate, esophagus or similar passageways. Typically, implants for such purposes are deployed in different ways, particularly for vascular stents by introducing them percutaneously and positioning the devices to the target region and expanding them. Expansion can be assured e.g. by mechanical means, like balloon or mandrel expansion, or by using super elastic materials that store energy for self-expansion. These implants are designed to keep the lumen of the passageway open and remain as a permanent implant within the body. Conventional stents for different applications comprise monofilament coil wires (U.S. Pat. No. 4,969,458), thin-walled metal cylinders with axial slots (see U.S. Pat. Nos. 4,733,665; 4,739,762; and 4,776,337) or welded metal cages (see U.S. Pat. Nos. 4,733,665 and 4,776,337). These stents are conventionally from materials such as, e.g., polymers, organic fabrics and biocompatible metals, such as stainless steel, gold, silver, tantalum, titanium, magnesium and shape memory alloys, such as Nitinol.
Recently, it was shown that the safety and/or efficacy of a stent can be significantly improved by incorporating beneficial agents, for example drugs that are delivered locally. Implants with drug-releasing coatings are, for example, described in U.S. Pat. Nos. 5,869,127; 6,099,563; 6,179,817; and 6,197,051, particularly for stents with drug elution. European Patent Publication No. 1466634 A1 describes a stent design with drug reservoirs by introducing through-holes either in metallic or polymeric stents by laser cutting, etching, drilling or sawing or the like.
However, the incorporation of beneficial agents can result in beneficial effects like improved safety or efficacy, but after a period of time with the degradation, uptake or release or diffusion of beneficial agents like biologically, pharmacological or therapeutic agents, the underlying implant material can substantially arise as a long-term issue like causing allergic reactions, chronic inflammation or even thrombosis and other severe complications.
For example, a stent based local delivery of beneficial agents is used to address various potential issues, and the most relevant in connection with vascular stenting is known as re-stenosis. Re-stenosis can occur after stent implantation or angioplasty interventions and is basically an inflammation response of the tissue resulting in cell proliferation, particular of smooth muscle cells, within the vessel wall and re-narrowing of the vessel lumen. To treat this complication, re-intervention and re-vascularisation treatments are necessary that again incur costs for medical care and risks to the patient. The use of drugs that can reduce inflammation or proliferation it was shown that the risk of re-stenosis could be reduced significantly. For example, U.S. Pat. No. 5,716,981 describes a stent with a surface-coating comprising a composition of a polymer carrier and paclitaxel (a well-known drug that is used in the treatment of cancerous tumors).
However, surface coatings may have some drawbacks with regard to the controlled release of beneficial agents, because the volume of the incorporated beneficial agent is relatively low compared to the surface area of the stent resulting in a short diffusion way for discharging into the surrounding tissue. The release profiles are typically of a first order kinetics with an initial burst and an asymptotic rapid release. Instead, it is more appropriate and desired to have a linear and constant control over the release of a drug. This disadvantageous effect can be partially compensated by increasing the thickness of a surface coating, but an increase of coating thickness, typically above a range of 3-5 μm, increases the stent wall thickness resulting in reduced flow cross-section of the vessel lumen, and furthermore may increases the profile of the stent resulting in more traumatic deposition of the stent and difficulties in placing them into small vessels. On the other hand, the use of polymer coatings on stent surfaces can be associated with a higher and significant risk of thrombosis, due to insufficient re-endothelialization of the vessel wall and pertinent presence of less or insufficiently biocompatible material. Recent clinical studies have also revealed that the use of polymers in drug-eluting stents is one of the causes for late thrombosis and a higher risk of myocardial infarction associated with the use of drug-eluting stents.
One conventional proposed solution is provided in U.S. Pat. No. 6,241,762 which describes a stent non-deforming strut and link elements that comprise holes without compromising the mechanical properties of the device as a whole. The holes are used as discrete reservoirs for delivering beneficial agents to the device implantation site without the need for a surface coating on the stent. One disadvantage of this design is that due to the mechanical requirements the width and the geometry of the basic stent design disclosed comprises a more traumatic design compared to established bare metal stents. Another drawback is that the arrangement of discrete holes contradicts to the requirement of homogeneously distributed drug on the surface of such a device, since it is well known that the homogeneous distribution of the drug is required for sufficient efficacy of drug-release and avoiding e.g. toxic accumulation of drug with certain tissue areas. In U.S. Publications Nos. 2003/0082680 and 2004/0073294, a solution to the problem of controlling release kinetics from a stent is described, that allows the deposition of multiple deposits of different polymer only and drug/polymer into discrete hole like reservoirs to achieve a wide variety of release kinetics which cannot be achieved from a surface coating. A further issue with this conventional approach may also be, that the control of the release profile requires a polymer/drug composition. Additionally, the stent is based on metal that in general can also induce adverse effects due to corrosion and release of metal ions in the mid and long term. Moreover, the loading of discrete reservoirs with a drug/polymer composition is complex and costly in terms of manufacture, in particular because the manufacturing allows no spray or dip coating but requires accurate dispensing technology.
Typically, implants are made of solid materials, either polymers, ceramics or metals. To provide improvements of engraftment or ingrowth of the surrounding tissue or adhesion, or to enable drug-delivery, implants have also been produced with porous structures. Different methods have been established to obtain either completely porous implants, particularly in the orthopedic field of application, or implants having at least porous surfaces, wherein a drug may be included for in-vivo release.
U.S. Patent Publication No. 2004/220659 describes endoprosthesis devices including stents, stent-grafts, grafts, vena cava filters, balloon catheters and the like made from porous PTFE. One drawback of this solution is that PTFE in nature is a smooth material that may not allow attachment of cells to promote re-endothelialization or engraftment, and complete removal of siloxane that itself has inflammatory potential is difficult to obtain, and the defects created by the removal of siloxane are inherently very small due to the molecular size of siloxane. Moreover, the hydrophobic nature of PTFE limits the use of less lipophilic drugs due to the surface tension that decreases the adsorption into such like porous structure.
European Patent Publication No. 1 319 416 describes a porous metallic stent coated with a ceramic layer with incorporation of a drug. The metallic pores are induced by electro pitting at the surface. One significant disadvantage is that the pore sizes are difficult to control, the pores are inherently provided only at the surface and are not interconnected throughout the complete implant body; furthermore, electro pitting can also affect the mechanical properties of the material resulting in increased fatigue or corrosion of the used implant material.
European Patent Publication No. 0 875 218 describes a metallic prosthesis and particularly a stent having a plurality of pores, and a therapeutic medication loaded into the pores of the metallic prosthesis, whereby the metallic implant is made of a sheet or tube based on porous metal wire, a sintered stainless steel, a sintered elemental metal, a sintered noble metal, a sintered refractory metal, and a sintered metal alloy. Significant disadvantages may be related to control of the pore sizes and geometries and respective porosities, particularly to control the net shape after the sintering procedure Moreover, such described solution is based on selection of fibers or particles that are sintered without any fillers so that sintering will result in a higher density of the structural materials.
International Publication WO 2007/003516 describes medical implants made of a porous composite material which comprises reticulating agents like metals, fibers, fullerenes etc., embedded in a polymeric, i.e. organic matrix. This publication also describes a thermal treatment of such materials, which may lead under partial decomposition of the polymer to a composite of a porous structure determined by the reticulating agents, hold together by carbonaceous material. In such materials, the porous structure is likely determined by the geometry of the reticulating agents and their three-dimensional alignment. The exemplary drawback of such materials, if the organic matrix is decomposed to a certain extent, is that the mechanical properties are deteriorated, so that such materials with a structure of reticulating agents held together by carbonaceous material cannot be used for supporting structures due to their brittleness.
The preferences for implants are increasingly complex, because the material properties should also meet certain mechanical specifications. Furthermore, the provision of functions, such as drug-release requires a significant drug amount to be released and bio-available. Therefore a sufficient compartment volume for desorption or deposition of drug itself should be provided without affecting the constructive properties of an implant, particularly its physical properties.
One of the objects of the present invention is to overcome the above-described deficiencies.
There may be a need for porous materials to provide implant functionality with additional properties for drug-release or enhanced biocompatibility or the like.
According to an exemplary embodiment of the present invention, it may be preferable to provided an implantable medical device or part thereof, e.g., a stent, having a supporting structure comprising a non-particulate inorganic carbon material.
In another exemplary preferred embodiment, the device can be provided which may be any conventional type of a stent, for example, one of a stent structured or configured for maintaining the patency of at least one of the esophagus, trachea, bronchial vessels, arteries, veins, biliary vessels and other similar body passageways in animals or human beings.
The stent according to an exemplary embodiment of the present invention can be expandable from a contracted state suitable for insertion into a vessel to an expanded state in which the stent supports the surrounding tissue, and may be self-expandable.
According to still another exemplary embodiment of the present invention, the non-particulate inorganic carbon material may include a bulk carbon material, a composite material comprising inorganic carbon and a further inorganic material, and/or a composite material comprising inorganic carbon and a further organic material.
For example, the exemplary inorganic carbon material can include at least 20% by weight of carbon, preferably at least about 50% by weight, more preferably at least 80% by weight, such as at least about 90% by weight, or at least about 95% by weight. In an exemplary embodiment, the device or stent can entirely consist of the inorganic carbon material. The inorganic carbon may include graphite, diamond-like carbon, pyrolytic carbon, turbostratic carbon, glassy and/or vitreous carbon.
In further exemplary embodiments of the present invention, the device or stent can have a supporting structure made of or comprising glassy carbon or vitreous carbon, e.g., a non-graphitizing type of inorganic carbon material, which combines glassy and ceramic properties with those of graphite. Optionally, the vitreous or glassy carbon material may include other materials, such as metals, alloys, ceramic, polymers, or the like, preferably in minor amounts.
According to still another exemplary embodiment of the present invention, the inorganic carbon material includes a composite material comprising inorganic carbon as described above, and a further inorganic material selected from, e.g., at least one of a metal, a metal alloy, or a metal compound.
According to a further exemplary embodiment of the present invention, the inorganic carbon material can include a composite material comprising inorganic carbon as described above, and a further organic material selected from, e.g., a polymer, a copolymer, an oligomer, and/or a polymer composite.
In still further exemplary embodiments, the supporting structure and/or the inorganic carbon material can be porous, preferably with an open porous structure, e.g., having a plurality of interconnected pores. Open porous can mean but not limited to that the pores are interconnected. The exemplary supporting structure and/or the inorganic carbon material can have a porosity in the range of about 10 to 90%, preferably about 30 to 90%, further preferably about 50 to 90%, in particular about 60%., and the average pore size of the pores is in a range of about 5 nanometer (nm) to 5000 micrometer (μm), preferably about 10 nm to 1000 μm, more preferably about 20 nm to 700 μm. Porosity can mean but not limited to the ratio between the net volume of the free available pore space in the structure, and the total volume of the supporting structure including all spaces and pores and the material itself. Porosity, pore sizes and pore size distributions may be measured, e.g., by an absorption method, such as N2-porosimetry. Such porosity may provide a possibility for a large storing capacity with respect to the remaining mass of the stent, or stent section. In addition, such pore sizes may allow a structure which is capable of being used for human stents, while obtaining a structure being capable to store an considerable amount of e.g. an active agent, and/or a structure allowing in growth of surrounding tissue after implantation.
According to an exemplary embodiment of the present invention, such structure may allow to provide a stent with at least a porous section or being totally made of porous material, which is capable of storing e.g. an active agent without the need to provide a cavity. The size of a particle, a space, a pore or a polyhedron can mean but not limited to its volume or as an alternative the largest dimension. In certain exemplary embodiments, the interior of the pores can be coated with a coating as desired, e.g., to improve biocompatibility or adhesion of active ingredients such that e.g. an active agent may be released in a defined rate.
According to an exemplary embodiment of the present invention, the pores in a first hierarchy can substantially cover a convex polyhedron. Thus, the cavities formed by the pores have an appropriate shape for receiving e.g. an active agent.
According to an exemplary embodiment of the present invention, at least a part of the pores in a second hierarchy substantially cover a combination of a convex polyhedron and at least one partial convex sub-polyhedron, whereas the size of the polyhedron is larger than or equal to the size of the sub-polyhedron. The pores may also constitute of a plurality of interconnected sub-pores. A convex polyhedron means a polyhedron without pitching in edges.
A pore substantially covering a polyhedron can mean but not limited to that each of the particles imaginary is tangent to a plane of the polyhedron covered by the pore. It should be understood that in case of tubular pores the tubes having a cross section of a convex polygon in equivalent interpretation to the convex polyhedron.
Pores may have a first hierarchy substantially covering a first space, and a second hierarchy covering a space extending over the first space. The second hierarchy may also include further hierarchies in the aforementioned manner.
According to an exemplary embodiment of the present invention, a ratio between the size of the polyhedron and the sub-polyhedron is in the range of about 1:0.5 to 1:0.001, preferably about 1:0.4 to 1:0.01, preferably about 1:0.4 to 1:0.01, and more preferably about 1:0.2. Such exemplary ratio may provide an optimal ratio to achieve a particular relation between the volume of the material structure, the pores and the stability of the structure.
According to still another exemplary embodiment, only parts of the stent can be made of the inorganic carbon material, for a subsequent assembly of the stent from such and optionally other parts, and such part of the stent can determine at least a part of a form of the stent. In such exemplary embodiments, the part may have a form out of a group consisting of a ring, a torus, a hollow cylinder segment, a tube segment, and/or a web structure.
According to a further exemplary embodiment of the present invention, the supporting structure of the stent can have a plurality of walls, whereas the walls can enclose a lumen for storing at least one active ingredient, and the walls are made of or comprise an inorganic carbon material and which may be adapted or structured to allow a fluid communication between the lumen and the exterior of the device for releasing the stored ingredient.
In such exemplary embodiments, the material can be non-porous and the walls have at least one opening connecting the enclosed lumen with the exterior of the device, to allow a release of active ingredients. Preferably, the opening is a hole. Alternatively, the material can be porous as defined above, having a plurality of interconnected pores for releasing an active ingredient through porous walls.
In further exemplary embodiment, a stent is provided, whereas the lumen can have an extension in a longitudinal direction of the stent and along a circumference of the stent, which may be substantially larger than a radial extension of the lumen.
In a further exemplary embodiment, a stent can be provided, comprising a first tube and a second tube concentric to the first tube, whereas the lumen is enclosed between the first and second concentric tube, and at least a part of the first and/or second tube can comprise the carbon material.
In a further exemplary embodiment, a stent can be provided, which can comprise a first ribbon helically wound around a tubular space and a second ribbon helically wound around the tubular space corresponding and concentric to the first ribbon, wherein the lumen is enclosed between the first and second concentric ribbons, and at least a part of the first and/or second tube comprises the carbon material.
In a further exemplary embodiment, a stent can be provided, whereas the stent can be formed by a plurality of hollow annular elements each having a sub-lumen, which annular elements can be arranged such that each annular element circumferences a tubular space and each annular element has a different inclination from an adjacent abutting annular element, wherein adjacent annular elements are joined at an abutting location to form a passage between two abutting annular elements. Optionally, the annular elements can comprise openings facing the exterior of the tubular space.
In a further exemplary embodiment, a stent can be provided formed of a brick wall structured mesh of hollow struts, whereas continuous struts can extend in a longitudinal direction, which may be connected by linking struts. Optionally, the brick walled structure totally may circumference a tubular space, such that the brick walled structure repeats periodically and perpetually along the circumference.
In a further exemplary embodiment, a stent can be provided formed by a plurality of hollow annular wave elements each having a sub-lumen, which annular wave elements can be arranged such that each annular element circumferences a tubular space and each annular element abutting an adjacent annular element, wherein adjacent annular elements are joined at an abutting location to form a passage between two abutting annular elements. Optionally, the tubular space can have a shape of a bifurcated tube.
According to an exemplary embodiment of the present invention, the stent can include at least one active ingredient. The active ingredient may provide an active therapy or prophylaxis with an as such passive element of a stent.
The exemplary embodiments of the present invention may also satisfy the preference for porous implants, whereas the pore size, the pore distribution and the degree of porosity can be adjusted without deteriorating the physical and chemical properties of the material essentially. Typically, with increasing degree of porosity the mechanical properties, such as hardness and strength decrease over-proportionally. This is particularly disadvantageous in biomedical implants, where anisotropic pore distribution, large pore sizes and a high degree of porosity are required, whereas simultaneously a high long-term stability with regard to biomechanical stresses is necessary.
The exemplary embodiments of the present invention can also satisfies the preference for implant materials with bioactive properties that overcome the drawbacks of corrosive and potentially toxic ion releasing metals or ceramics. In addition, the materials shall can have properties that allow adsorbing and desorbing lipophilic as well as hydrophilic beneficial agents.
The exemplary embodiments of the present invention can also satisfy the preference for providing drug-release function and improving the availability of drug by increasing the overall volume of the porous compartment that contains the drug without affecting adversely the design of the device. For example, the current design of drug-eluting stents is based on non-porous scaffolds that have to be coated resulting in an increase of the stent strut thickness. Increasing the thickness results in adverse properties, such as increasing the profile of the stents within the target vessels, which can limit the use to large vessels, or which can be correlated to mechanically induced, haemodynamic-related thrombosis.
The exemplary embodiments of the present invention may also satisfy the preference for beneficial agents comprising, incorporating or releasing drug-eluting stent which after implantation can remain permanently in the body to fulfill, e.g., a permanent supporting function.
One aspect of the exemplary embodiments of the present invention is to provide an implant made out of a bioactive material that comprises improved biocompatibility, facilitates engraftment and reduces inflammatory or adverse long-term effects.
According to another exemplary embodiment of the present invention, a stent can be provided which at least at the surface contacts body tissue or physiologic fluids with a carbon-containing bioactive material that comprises improved biocompatibility, facilitates engraftment and reduces inflammatory or adverse long-term effects.
According to another exemplary embodiment of the present invention, a stent can be provided with a porous compartment or hollow lumen as a reservoir for incorporation of beneficial agents.
In accordance with another exemplary aspect, a stent can incorporate biologically active, therapeutically active, diagnostic or absorptive agents.
According to a further exemplary object of the present invention, a simple and cost-effective, flexible process can be provided for the manufacturing of such stents.
In accordance with one aspect of the exemplary embodiments of the present invention, an implantable stent can be provided for maintaining patency of the esophagus, trachea, bronchial vessels, arteries, veins, biliary vessels, capillaries, lumen and/or other similar passageways.
In accordance with another aspect of the exemplary embodiments of the present invention, a stent may be provided according to the other aspects whereby the stent incorporates biologically active, therapeutically active, diagnostic or absorptive agents.
In accordance with yet a further aspect of the exemplary embodiments of the present invention, an implantable stent may be provided comprising an expandable stent structure, a porous compartment or reservoir within the structure and/or a plurality of openings in the stent structure.
Each of the exemplary features and exemplary embodiments described above may be combined, where it is appropriated, without departing from the spirit of the present invention.
These and other objects, features and advantages of the present invention will become apparent upon reading the following detailed description of embodiments of the present invention.
Further objects, features and advantages of the present invention will become apparent from the following detailed description taken in conjunction with the accompanying figures showing illustrative embodiments of the present invention, in which:
Throughout the figures, the same reference numerals and characters, unless otherwise stated, are used to denote like features, elements, components or portions of the illustrated embodiments. Moreover, while the subject invention will now be described in detail with reference to the figures, it is done so in connection with the illustrative embodiments. It is intended that changes and modifications can be made to the described embodiments without departing from the true scope and spirit of the subject invention.
The terms “active ingredient”, “active agent” or “beneficial agent” as used herein can include but not limited to any material or substance which may be used to add a function to the implantable medical device. Examples of such active ingredients can include biologically, therapeutically or pharmacologically active agents, such as drugs or medicaments, diagnostic agents, such as markers, or absorptive agents. The active ingredients may be a part of the first or second particles, such as incorporated into the implant or being coated on at least a part of the implant. Biologically or therapeutically active agents may comprise substances being capable of providing a direct or indirect therapeutic, physiologic and/or pharmacologic effect in a human or animal organism. A therapeutically active agent may include a drug, pro-drug or even a targeting group or a drug comprising a targeting group. An “active ingredient” according to exemplary embodiments of the present invention may further include but not limited to a material or substance which may be activated physically, e.g., by radiation, or chemically, e.g., by metabolic processes.
The term “biodegradable” as used herein can include but not limited to any material which can be removed in-vivo, e.g., by biocorrosion or biodegradation. Thus, any material, e.g., a metal or organic polymer that can be degraded, absorbed, metabolized, or which is resorbable in the human or animal body may be used either for a biodegradable metallic layer or as a biodegradable template in the embodiments of the present invention. In addition, as used herein, the terms “biodegradable”, “bioabsorbable”, “resorbable”, and “biocorrodible” are can include but not limited to meaning to encompass materials that are broken down and may be gradually absorbed or eliminated by the body in-vivo, regardless whether these processes are due to hydrolysis, metabolic processes, bulk or surface erosion.
The terms “lumen”, “compartment” or “reservoir” can include but not limited to describing a an essentially closed hollow space, other than a pore or pore system, enclosed by walls of the implant material. Examples of a lumen are shown, e.g., in
The term “porous” as used herein can include but not limited to a property of a material, which is determined by the presence of a plurality of interconnected pores. The volume of the pores can be assessed by measuring the porosity of the material as further defined herein. “Porous” likely does not include holes like boreholes or the like.
The term “supporting structure” can include but not limited to designating the bulk structure of the device, e.g., the device body. To the contrary, a coating may likely not be a part of a supporting structure.
The terms “implant”, implantable device” and the like can define but not limited to a stent as described herein.
The exemplary embodiments of the present invention are described in greater detail herein with reference to the exemplary embodiments illustrated in the accompanying drawings. The following description makes reference to numerous specific details in order to provide a thorough understanding of the present invention. All exemplary aspects and features described herein may be combined as desired. However, each and every specific detail needs not to be employed to practice the present invention.
In one exemplary embodiment, the porous implant can comprise a tubular structure with an inner lumen along the longitudinal axis. The pores are interconnected and constitute a porous compartment or reservoir. In certain exemplary embodiments, the structure comprises at least one or a plurality of perforation/s within the porous wall, herein referred to as an opening or openings.
a shows an exemplary embodiment of an implant or stent 10 with a tubular or essentially cylindrical structure according to the present invention. A cross-sectional view of the exemplary implant 10 is shown in
The length of the exemplary stent can be depending not on the intended use of the stent, e.g., in a range of about 100 μm to 100 cm, such as from about 1000 μm to 10 cm, or from about 5 mm to 60 mm, or even from about 7 mm to 40 mm. The diameter can be selected, e.g., in a range from about 5 nm to 20 cm, such as from about 1000 nm to 10 cm, or from about 500 μm to 10 mm, or even from about 500 μm to 10.000 μm. Furthermore, in a further exemplary embodiment, the ratio of length to width of the exemplary stent tube can be selected from about 20:1 to 10:1, more preferable from about 8:1 to 5:1 and even more preferable from about 4:1 to 2:1. However, the ratio may be dependent on the intended use of the stent and the capacity of the porous compartment or reservoir. The size of the porous compartment, e.g., the overall volume of pores, is not only adjustable by selecting the dimensional sizes of length and width and diameter, and also by appropriate design of pore structure and/or pore volume. The openings can have a round shape, ellipsoid shape, rectangular shape or any other regular or irregular geometry or any combination thereof. The porous compartment may allow for the incorporation or release of beneficial agents, such as biologically active, therapeutically active, diagnostic or absorptive agents or any combination thereof. Furthermore, the porous compartment also allows the absorption of compounds from physiologic fluids into the compartment inside the stent structure. One having ordinary skill in the art can determine the appropriate option in terms of dimension and exemplary embodiment of porous compartments and openings depending on the target area with the body of the living animal or human being. For example, an exemplary embodiment for use as an artery or vein graft should have appropriate dimensions for implanting the device. Furthermore, the intended release of a therapeutic agent locally to the surrounding vessel wall may further utilize appropriate dimensions of the pores to sufficiently absorb and release the beneficial agents.
In another exemplary embodiment, the porous a stent may have a shape of a helical tube of a band-like or stripe-like structure. The pores in the stent structure are interconnected and constitute a porous compartment or reservoir. The helical structure may allow a flexible distortion of the stent due to the design. The structure may comprise at least one or a plurality of perforation/s within the porous wall, herein referred to as an opening or openings.
a shows an exemplary embodiment of a possible stent structure 70 according to the present invention which can comprise a helical tube of a band-like or stripe-like structure. A cross-sectional view of the exemplary implant 70 is shown in
For example, in one exemplary embodiment for use as a tracheal or bronchial stent, the implant may have appropriate dimensions for implanting the device.
In further exemplary embodiments, the helical stripe may comprise peaks or serpentines, either symmetrically or asymmetrically, or any desired pattern of peaks and/or serpentines. In addition, a plurality of peaks and/or serpentines may be embedded in any desired combination, whereby also the angles and radius can be different.
Furthermore, the peaks and serpentines can be of rectangular shape, either with rounded or without rounded edges of the struts. The struts can have different width and/or depth, i.e. aspect ratios, at different sections along their structures. In certain exemplary embodiments, it can be preferable to have combination of rectangular or rounded peaks and/or serpentines or any combination thereof.
In a further exemplary embodiment, the porous implant comprises a stent having a double helical structure of interconnected, helically winded tubes. The pores can interconnected and constitute a porous compartment or reservoir. The structure may comprise at least one or a plurality of perforation/s or openings within the porous wall, as described above.
a shows another exemplary embodiment of an implant according to the present invention, e.g., a stent 100 having a double helical structure of interconnected, helically winded tubes. The structure may comprise at least one opening 110. The cross-sectional view of the implant in
In one exemplary embodiment, the helical tubular stent may comprise more than two helices. The length of the implant can be in a range as described above.
In another exemplary embodiment, the porous implant can be a mesh-like tube or lattice. According to a specific exemplary embodiment, a rectangular pattern can be used for the implant in a two-dimensional view
a shows a rectangular pattern 130 in a two-dimensional view according to one exemplary embodiment of the present invention. For example, the lattice structure can comprise, in a longitudinal direction, continuous struts 140 that may be connected by linking struts 150. The lattice 130 may be formed to a tubular implant 160 as described in
The exemplary lattice structure can comprise in longitudinal direction continuous struts that are connected by linking struts. The lattice can be formed to a tubular implant as described in the drawings. The struts may be porous and can comprise an interconnected porous compartment or respective reservoir. In certain exemplary embodiments, the structure may also comprise at least one opening.
The length of the exemplary implant can be in a range as described above.
One having ordinary skill in the art may determine the appropriate option in terms of dimension and embodiment of openings depending on the target area with the body of the living animal or human being. For example, in one specific exemplary embodiment for use as a coronary or peripheral stent, the implant should have appropriate dimensions for implanting the device. The angle between one linking strut and the continuous struts can be about 90°, in other exemplary embodiments, the angle can be modified to any preferable pattern with angles from about 0.1° to 179°. The porous lattice tube may, e.g. comprise at least two continuous struts that are linked. The number and distance of continuous and linking struts can be varied according to the intended mechanical properties, the required volume of the porous compartment or respective reservoir. In addition, the orientation of the linking struts can be varied. Furthermore, an asymmetric design of linking struts, e.g., identical numbers and/or orientation and/or distances and/or angles, may be used or asymmetric designs with different numbers and/or orientations and/or distances and/or angles. Particularly for expandable stents it may be desirable to select an exemplary embodiment that can be appropriate, whereby a person skilled in the art can easily identify the appropriate design e.g. by using finite element analysis to determine the optimal configuration. The thickness of the struts can play an important role for elastomechanical properties of the implant. For expandable devices, but not limited to strut thicknesses in a range of about 10 μm up to 500 μm, more preferable from about 50 μm to 400 mm and even more preferable from about 70 μm to 200 μm may be used. The thickness can be larger or smaller, depending on the requirements of the implant regarding mechanical or biomechanical stress occurring after implantation. For example, a person skilled in the art can select larger thicknesses for implants that are used as peripheral stents for arteries in the knee or below the knee.
In addition, the aspect ratio, e.g., the ratio between width and depth of a strut, may be varied as appropriate. In certain exemplary applications that utilize a low profile struts with lower depth may be used. Therefore, the aspect ratios can be in a range from about 20:1 to 1:20, such as from about 10:1 to 1:10 or from about 2:1 to 1:2.
The drawings illustrate the basic aspects of the exemplary embodiments of the present invention and are not limited to any of the aforesaid aspects. For example, the edges of the struts can be rounded. In some exemplary embodiments, for example, in order to increase the overall surface or to optimize the stress distribution for expandable implants, serpentines and peaks may be embedded into the struts. For example, the linking struts may comprise at least one peak or one serpentine with two peaks. The orientation of the peaks or serpentines can be varied, e.g., a left-hand oriented peak or right-hand oriented serpentine with a right-hand oriented peak first and a right-hand oriented peak second or vice versa. In certain exemplary embodiments, the modified linking struts may all have the same design; in other exemplary embodiments, the struts can have alternating patterns or any different pattern or combination thereof. In further exemplary embodiments, the continuous struts may comprise peaks or serpentines, either symmetrically or asymmetrically, or both the continuous struts and the linking struts may comprise any desired pattern of peaks and/or serpentines. The exemplary design is not limited to one peak or one serpentine, it is also possible to embed a plurality of peaks and/or serpentines in any desired combination, whereby also the angles and radius can be different.
The peaks and serpentines can be of rectangular shape, either with rounded or without rounded edges of the struts. Furthermore, the struts can have different width and/or depth, i.e. aspect ratios, at different sections along their structures. In some embodiments it can be preferable to have a combination of rectangular or rounded peaks and/or serpentines or any combination thereof.
In another exemplary embodiment, the open cells, e.g., the space between the struts, of the above described exemplary structure may comprise the struts and the struts comprise the open cells. Therefore, this specific embodiment has to be seen as a “negative” of the aforesaid embodiment.
a shows a open cell pattern 230 in a two-dimensional view. The lattice structure comprises narrow continuous struts 240 connected by broader linking struts 250.
In this exemplary embodiment, the continuous struts and linking struts comprise nodes at their intersections. The nodes can have different geometric shapes and dimensions. Particularly, the distances between the nodes, distances of linking struts and the segments of continuous struts between the nodes can be modified similar to the above described embodiments. Hence, also the modification of continuous struts and linking struts can be embedded as explained above.
In another exemplary embodiment, the porous implant can be a mesh-like tube with a rhombic shape of the open cells. The struts are porous and comprise an interconnected inner porous compartment or respective reservoir. The structure may also comprise at least one opening.
a and
The length and diameter of the implant can be in a range as described above.
The angle between the struts in the longitudinal axis may be about 30° to 90°, and the angle can be modified to any preferable pattern with angles from about 0.1° to 179°. According to another exemplary embodiment of the present invention, the angle between the struts in the rectangular axis is about 20° to 120°. The struts form at their intersections a node, whereby at least two nodes are comprised. The exemplary implant can comprise a segment between two nodes, hence, at least one segment can be included. The struts between the nodes may be linking struts. The number and distance of nodes and linking struts can be varied according to the intended mechanical properties, the required volume of the porous compartment or respective reservoir. In addition, the orientation of the linking struts can be varied. An asymmetric design of linking struts may also be used, i.e. identical numbers and/or orientation and/or distances and/or angles. Particularly for expandable implants it is desirable to select an embodiment that is appropriate, whereby a person skilled in the art can easily identify the appropriate design e.g. by using finite element analysis to determine the optimal configuration. The thickness of the struts can play an important role for elastomechanical properties of the implant. Strut thickness may be as described above.
Further, the aspect ratio, e.g., the ratio between width and depth of a strut, may be selected as described above.
In another exemplary embodiment, the porous implant or stent can comprise a tube with a parallel lattice with interconnecting links. The struts are porous and comprise an interconnected porous compartment or respective reservoir. In specifically preferable embodiments, the structure also comprises at least one opening or a plurality of openings.
a shows an exemplary embodiment of an undulated lattice 350 according to the present invention in a two-dimensional view, wherein the parallel, undulated struts 360 are interconnected by linking struts 370. The exemplary lattice 350 may be formed to a tubular implant 380 as illustrated in
In the longitudinal axis, at least two continuous struts are interconnected by at least one linking strut. The length and diameter of the implant can be in a range as described above.
The porous compartment allows for the incorporation or release of beneficial agents, preferably biologically active, therapeutically active, diagnostic or absorptive agents or any combination thereof. Furthermore, the porous compartment can also facilitate the absorption of compounds in physiologic fluids into the compartment. One having ordinary skill in the art can determine the appropriate option in terms of exemplary dimension and exemplary embodiment of openings depending on the target area with the body of the living animal or human being. For example, in one exemplary embodiment for use as a biliary or coronary stent, the implant must have appropriate dimensions for implanting the device. The angle between one linking strut and the continuous struts is about 10° to 160°, but the angle can be modified to any preferable pattern with angles from about 0.1° to 179°. The number and distance of continuous and linking struts can be varied according to the intended mechanical properties, the required volume of the porous compartment or respective reservoir. The continuous struts may comprise a symmetric or asymmetric pattern of wave-like peaks, whereby the orientation of the peaks can be alternating or non-alternating. The angle of the peaks can be varied from about 10° to 179°, such as from about 15° to 160°, or from about 25° to 120°. In addition, the orientation of the linking struts can be varied. Furthermore, in specific embodiments it is required to have asymmetric design of linking struts may be used, i.e. identical numbers and/or orientation and/or distances and/or angles.
The design of different porous implants is not limited to the above described basic geometric embodiments. For example, implants may also have a combined geometry of the tube, i.e. bifurcated tube at one or more sides or at one lateral end or at both lateral ends and any combination thereof. It could be preferable to implant stents or stent grafts into bifurcated vessels for example, therefore it is useful to have an implant design that follows the natural anatomy of the targeted organ, organ structure or organ vessel.
Moreover, the implants or stents may have different diameters at the ends or at any section of the implant, e.g. to address the anatomy of target vessels that have a narrowing profile. Another exemplary embodiment comprises at least one cut out within the structure, e.g. for use in bifurcating vessels or complex anatomical structures. The implants may be used in combination, e.g. to allow the implantation of stent into a bifurcation area of arteries or veins.
Exemplary Materials
According to an exemplary embodiment of the present invention, the supporting structure of the stent, or part thereof can comprise an inorganic carbon material, and/or may optionally consist of the inorganic carbon material.
The inorganic carbon material for use in the exemplary embodiments of the present invention may be any carbon material, which is different from an organic polymer material. Preferably, the inorganic carbon material can be a homogenous, e.g., a non-particulate material. The inorganic carbon material can, for example, include at least one of a bulk carbon material, a composite material comprising inorganic carbon and a further inorganic material, or a composite material comprising inorganic carbon and a further organic material.
For example, the inorganic carbon material can include at least 20% by weight of carbon, preferably at least about 50% by weight, more preferably at least about 80% by weight, such as at least about 90% by weight, or at least about 95% by weight.
The inorganic carbon can include at least one of graphite, diamond-like carbon, pyrolytic carbon, turbostratic carbon, glassy or vitreous carbon, amorphous carbon, or the like.
Furthermore, in exemplary embodiments, the inorganic carbon material may be reinforced as conventionally known with minor amounts of e.g. carbon particles, carbon fibers, carbon nanotubes, fullerenes, fullerene onions, metallo-fullerenes, graphite fibers or particles or diamond, e.g. in order to improve the elastomechanical properties. Preferably, such particulate or fibrous materials can be added to the inorganic carbon material in an amount that substantially does not determine or influence the material or pore structure of the inorganic carbon material. Particularly, there are no pores in the inorganic carbon material being determined or confined by an alignment of fillers, fibers or particles as described herein.
The inorganic carbon material as described herein can be a substantially homogenous, optionally reinforced material, which, if porous, may include pores created by incorporating removable pore-formers into a precursor material and subsequently removing such pore-forming materials from the inorganic carbon material.
In further exemplary embodiments of the present invention, the device or stent has a supporting structure can comprise or even consisting substantially of glassy carbon or vitreous carbon, e.g., a non-graphitizing type of inorganic carbon material, which combines glassy and ceramic properties with those of graphite. Some of properties of this material can be, e.g., its biocompatibility, bio-inertness, and resistance to chemical attack. Glassy carbon is a conventional material, widely used, e.g., as an electrode material in electrochemistry, and may be produced from organic precursor materials, such as polymers or phenolic resins at temperatures up to about 3000° C. by carbonization, and may be widely varied in its physical properties.
Without being bound to any specific theory, the structure of glassy carbon can be about 100% sp2-hybridized carbon, i.e. a graphite or fullerene like structure. Other models can assume that both sp2 and sp3 -bonded atoms may be present. A later model can be based on the assumption that the molecular orientation of the polymeric precursor material is memorized to some extent after carbonization. Thus, it may be assumed that the structure bears some resemblance to that of a polymer, in which the “fibrils” are very narrow curved and twisted ribbons of graphitic, and thus inorganic, carbon. However, more recent research has suggested that glassy carbon has a fullerene-related structure. Basically, glassy or vitreous carbon can consists of two-dimensional structural elements (sp2-C) and does not generally exhibit ‘dangling’ bonds, like, e.g., amorphous carbon does.
In a further exemplary embodiment, the inorganic carbon material may comprise amorphous carbon, e.g., a glassy carbon material that likely does not have any crystalline structure, and can include a certain amount of sp3-carbon structural elements. As with all glassy materials, amorphous carbon reveals some short-range order, but there is no long-range pattern of atomic positions.
In further exemplary embodiments, the inorganic carbon material may comprise diamond-like carbon (DLC) which is also an amorphous carbon material that displays some of the properties of diamond. Such materials contain significant amounts, for example, up to about 100%, of sp3 hybridized carbon atoms, whereas the carbon atoms may be arranged in a cubic lattice or a hexagonal lattice, or mixtures thereof.
Furthermore, mixtures of amorphous, diamond-like, vitreous, glassy, or other carbon materials may be used for preparing the supporting structure of the devices of the present invention.
Optionally, the inorganic carbon material, such as amorphous, diamond-like, vitreous or glassy carbon material may be mixed with other materials, such as metals, alloys, ceramic, polymers, or the like, preferably in minor amounts, e.g., less than about 30% by weight, preferably less than about 10% by weight.
According to the exemplary embodiment of the present invention optionally porous stents can be provided which contain at minimum a carbon content of 20% by weight, preferably sp2 carbon or, in specific embodiments, sp3 carbon or any mixture thereof. Without binding to a specific theory it was demonstrated that inorganic materials with sp2 carbon or sp3 carbon contacted with physiologic fluids or living cells or tissue show bioinert or bioactive properties and are superior to other materials in terms of cytotoxicity, haemocompatibility, inflammation or engraftment and respective tissue or cell adhesion.
According to one aspect of the present invention, the optionally porous implant (e.g., stent) can comprise the carbon-material at least at one part of the surface contacted with physiologic fluids or cells or tissue. The exemplary embodiment of the present invention also can facilitate the use of different materials for different sections or parts of the exemplary implant.
According to an exemplary embodiment of the invention the inorganic carbon material includes a composite material comprising inorganic carbon as described above, and a further inorganic material selected from, e.g., at least one of a metal, a metal alloy, or a metal compound.
According to one exemplary embodiment, optionally porous, implant can comprises a combination of carbon materials as described above, and metal or metal alloys, e.g., metals and metal alloys selected from main group metals of the periodic system, transition metals, such as copper, gold and silver, titanium, zirconium, hafnium, vanadium, niobium, tantalum, chromium, molybdenum, tungsten, manganese, rhenium, iron, cobalt, nickel, ruthenium, rhodium, palladium, osmium, iridium or platinum, or from rare earth metals. The metal compound may also be selected from any suitable metal or metal oxide or from shape memory alloys any mixture thereof to provide the structural body of the implant. Preferably, the metal compound can be selected from the group of zero-valent metals, metal oxides, metal carbides, metal nitrides, metal oxynitrides, metal carbonitrides, metal oxycarbides, metal oxynitrides, metal oxycarbonitrides and the like, and any mixtures thereof. The metals or metal oxides or alloys used according to one exemplary embodiment may be magnetic. Examples can include—without excluding others—iron, cobalt, nickel, manganese and mixtures thereof, for example iron, platinum mixtures or alloys, or for example, magnetic metal oxides like iron oxide and ferrite. It may be preferable to use semi-conducting materials or alloys, for example semi-conductors from Groups II to VI, Groups III to V, and Group IV. Suitable Group II to VI semi-conductors are, for example, MgS, MgSe, MgTe, CaS, CaSe, CaTe, SrS, SrSe, SrTe, BaS, BaSe, BaTe, ZnS, ZnSe, ZnTe, CdS, CdSe, CdTe, HgS, HgSe, HgTe, or mixtures thereof. Examples for suitable Group III to V semi-conductors are GaAs, GaN, GaP, GaSb, InGaAs, InP, InN, InSb, InAs, AlAs, AIP, AISb, AIS and mixtures thereof. Examples for Group IV semi-conductors are germanium, lead and silicon. The semi-conductors may also comprise mixtures of semi-conductors from more than one group and all the groups mentioned above are included.
In other exemplary embodiments it can be preferable to select the material from metals or metal-oxides or alloys that comprise MRI visibility or radiopacity, preferably implants made from ferrite, tantalum, tungsten, gold, silver or any other suitable metal, metal oxide or alloy, like platinum-based radiopaque steel alloys, so-called PERSS (platinum-enhanced radiopaque stainless steel alloys), cobalt alloys or any mixture thereof.
Furthermore, biodegradable metals may be incorporated in carbon composites, which can include, e.g., metals, metal compounds, such as metal oxides, carbides, nitrides and mixed forms thereof, or metal alloys, e.g. particles or alloyed particles including alkaline or alkaline earth metals, Fe, Zn or Al, such as Mg, Fe or Zn, and optionally alloyed with or combined with other particles selected from Mn, Co, Ni, Cr, Cu, Cd, Pb, Sn, Th, Zr, Ag, Au, Pd, Pt, Si, Ca, Li, Al, Zn and/or Fe. In addition suitable are, e.g., alkaline earth metal oxides or hydroxides, such as magnesium oxide, magnesium hydroxide, calcium oxide, and calcium hydroxide or mixtures thereof. In further exemplary embodiments, the biodegradable metal-compound may be selected from biodegradable or biocorrosive metals or alloys based on at least one of magnesium or zinc, or an alloy comprising at least one of Mg, Ca, Fe, Zn, Al, W, Ln, Si, or Y. Furthermore, the implant may be substantially completely or at least partially degradable in-vivo. Examples for suitable biodegradable alloys comprise e.g. magnesium alloys comprising more than 90% of Mg, about 4-5% of Y, and about 1.5-4% of other rare earth metals, such as neodymium and optionally minor amounts of Zr; or biocorrosive alloys comprising as a major component tungsten, rhenium, osmium or molybdenum, for example alloyed with cerium, an actinide, iron, tantalum, platinum, gold, gadolinium, yttrium or scandium.
The metal or metal alloy may include in an exemplary embodiment, e.g.:
According to a further exemplary embodiment of the present invention, the inorganic carbon material can includes a composite material comprising inorganic carbon as defined above, and a further organic material selected from, e.g., at least one of a polymer, a copolymer, an oligomer, or a polymer composite. In further exemplary embodiments, the carbon material of the exemplary device can contain a coating, either partially or completely, to comprise a sandwich-like composite material and preventing the device from particulate formation due to mechanically induced damages or to enhance the elastomechanical properties. This exemplary material design can consist of the carbon material as the core and the coating material as the shell of the structural implant material. The coating materials may be selected from organic compounds.
Exemplary organic compounds or materials for such composites include biocompatible polymers, oligomers, pre-polymerized forms as well as polymer composites. The polymers used may be thermosets, thermoplastics, synthetic rubbers, extrudable polymers, injection molding polymers, moldable polymers, spinnable, weavable and knittable polymers, oligomers or pre-polymerizes forms and the like or mixtures thereof.
In an exemplary embodiment, the organic compounds or materials for such composites are selected from electrically conducting polymers, fluorescent or luminescent polymers. In specific exemplary embodiments, it can be useful to select the organic compound from biodegradable organic materials, for example—without excluding others—collagen, albumin, gelatin, hyaluronic acid, starch, cellulose (methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose-phtalate); furthermore casein, dextrane, polysaccharide, fibrinogen, poly(D,L lactide), poly(D,L-lactide-Co-glycolide), poly(glycolide), poly/hydroxybutylate), poly(alkylcarbonate), poly(orthoester), polyester, poly(hydroxyvaleric acid), polydioxanone, poly(ethylene, terephtalate), poly(maleic acid), poly(tartaric acid), polyanhydride, polyphosphohazene, poly(amino acids), and all of the copolymers and any mixtures thereof.
In another exemplary embodiment, the material can be based on a combination of non-particulate inorganic carbon materials as described above and inorganic composites or organic composites or hybrid inorganic/organic composites. The composite material can also comprise, as a functional additive in small amounts substantially not affecting the performance of the non-particulate inorganic material, e.g., to enhance visibility by diagnostic methods, organic or inorganic micro- or nano-particles or any mixture thereof. For example, these additive particles used in the exemplary embodiments can be selected from the group of zero-valent metals, metal oxides, metal carbides, metal nitrides, metal oxynitrides, metal carbonitrides, metal oxycarbides, metal oxynitrides, metal oxycarbonitrides and/or the like, and any mixtures thereof. The particles used in the exemplary embodiment of the present invention may be magnetic. It may be preferred to use semi-conducting particles. In one exemplar y embodiment, the semiconducting particles used can include core/shell particles and may have absorption properties for radiation in the wavelength region from gamma radiation up to microwave radiation, or the particles are able to emit radiation, particularly in the region of 60 nm or less, wherein it may be preferable to select the particle size and the diameter of core and shell in such a manner that the emission of light quantums in the region of about 20 to 1,000 nm is adjusted. In addition, mixtures of such particles may be selected which emit light quantums of different wavelengths when exposed to radiation.
In a further exemplary embodiment, the selected nanoparticles can be fluorescent, particularly preferred without any quenching.
It may further be preferable to select superparamagnetic, ferromagnetic, ferromagnetic metal particles. In one exemplary embodiment, the particles may be selected from polymers, oligomers or pre-polymeric particles. Examples of suitable polymers for use as particles in the present invention are hompopolymers, copolymers, prepolymeric forms and/or oligomers of poly(meth)acrylate, unsaturated polyester, saturated polyester, polyolefines like polyethylene, polypropylene, polybutylene, alkyd resins, epoxy-polymers or resins, phenoxy polymers or resins, phenol polymers or resins, polyamide, polyimide, polyetherimide, polyamideimide, polyesterimide, polyesteramideimide, polyurethane, polycarbonate, polystyrene, polyphenole, polyvinylester, polysilicone, polyacetale, cellulosic acetate, polyvinylchloride, polyvinylacetate, polyvinylalcohol, polysulfone, polyphenylsulfone, polyethersulfone, polyketone, polyetherketone, polybenzimidazole, polybenzoxazole, polybenzthiazole, polyfluorocarbons, polyphenylenether, polyarylate, cyanatoester-polymere, and mixtures of any of the foregoing.
Furthermore, polymer particles may be selected from oligomers or elastomers like polybutadiene, polyisobutylene, polyisoprene, poly(styrene-butadiene-styrene), polyurethanes, polychloroprene, or silicone, and mixtures, copolymers and combinations of any of the foregoing.
In another exemplary embodiment, at least a part of the particles can be selected from electrically conducting polymers, preferably from saturated or unsaturated polyparaphenylene-vinylene, polyparaphenylene, polyaniline, polythiophene, poly(ethylenedioxythiophene), polydialkylfluorene, polyazine, polyfurane, polypyrrole, polyselenophene, poly-p-phenylene sulfide, polyacetylene, monomers oligomers or polymers thereof or any combinations and mixtures thereof with other monomers, oligomers or polymers or copolymers made of the above-mentioned monomers. Further preferable can be monomers, oligomers or polymers including one or several organic, for example, alkyl- or aryl-radicals and the like or inorganic radicals, like for example, silicone or germanium and the like, or any mixtures thereof. Preferable may be conductive or semi-conductive polymers having an electrical resistance between 1012 and 1012 Ohm·cm. It may be preferable to select those polymers which can comprise complexed metal salts.
In other exemplary aspects of the exemplary embodiment, the additive particles can be selected from biodegradable particles like, for example—without excluding others—collagen, albumin, gelatine, hyaluronic acid, starch, cellulose (methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose-phtalate); furthermore casein, dextrane, polysaccharide, fibrinogen, poly(D,L lactide), poly(D,L-lactide-Co-glycolide), poly(glycolide), poly/hydroxybutylate), poly(alkylcarbonate), poly(orthoester), polyester, poly(hydroxyvaleric acid), polydioxanone, poly(ethylene, terephtalate), poly(maleic acid), poly(tartaric acid), polyanhydride, polyphosphohazene, poly(amino acids), and all of the copolymers and any mixtures thereof.
For example, the carbon phase of the non-particulate inorganic carbon material can comprise inorganic sp2 or sp3 carbon or any mixture thereof, like graphite, pyrolytic, turbostratic, glassy or vitrous carbon, diamond-like carbon or any mixture thereof.
In further exemplary embodiments, the implant can comprise a supporting structure of a non-particulate inorganic carbon material, e.g., a structural material made out of inorganic sp2 and/or sp3 hybridized carbon, whereby, partially or completely, the outer surface or both the outer and inner surface of the supporting structure can comprise a non-carbon material.
In another exemplary embodiment, the implant can comprise a structural material made out of a composite containing inorganic sp2 or sp3 or a mixture of sp2 and sp3 hybridized carbon.
Exemplary Material Structure
The porous compartment in the carbon material can be constituted by a plurality of single pores that are interconnected towards a network of pores.
According to an exemplary embodiment of the present invention, the pores can be also connected to the surfaces of the exemplary implant. For example, the degree of porosity is between about 10% and 95%, more preferable between about 30% and 90% and even more preferable between about 50% and 90%. The pores can be isotropic or anisotropic and the distribution of pores is preferably homogeneously throughout the implant structure. Preferable average pore sizes are in a range of about 5 nm to 5000 μm, more preferable from about 10 nm to 1000 μm and even more preferable from about 20 nm to 700 μm. In certain exemplary embodiments, it may be preferable to include hierarchical pore designs, e.g., pores with additional pores in the pore defining walls of such-like hierarchically structured pores. In these embodiments, the hierarchically structured pores have a larger size than the pores within the walls, whereby the pores in the walls can also be structured hierarchically.
According to an exemplary embodiment of the present invention, a hierarchical pore can be referred to as a first level hierarchy pore that has at minimum one or a plurality of a second level hierarchy pore within its wall whereby a second level hierarchy pore can comprise also a hierarchy pore itself. Preferably, the ratio of the radiuses of such like pores between the first level and the second level pore is 1:0.5 to 1:0.001, more preferable 1:0.4 to 1:0.01 and most preferable 1:0.2. A hierarchical design of pores allows to increase the pore volume significantly and the respective surface area within the structural implant body.
Furthermore, and without wishing to be bound to a specific theory, the structural design using a hierarchical structure of pores comprises surprisingly a higher mechanical stability compared to a design with similar pore volumes made out of non-hierarchic pores. Another exemplary advantage can be that in specific exemplary embodiments of the present invention, the first level pore can be designed in an dimension that allows tissue ingrowth or a higher contact surface and that the second or further level pores can be used to incorporate and/or release a beneficial agent.
In other exemplary embodiments, the structural implant body comprises smaller pores on the outer cross-sectional areas of the implant and larger pores at the inner cross-sectional parts or, alternatively, vice versa. Furthermore a gradient can be comprised with increasing or alternatively decreasing the pore sizes along the cross-sectional dimension. In further specific embodiments, there are multiple layers of interconnected pores, also interconnected across the layers, at least two layers or a plurality of layers, whereby the first layer comprises smaller pores, or optionally an aforesaid gradient of pore sizes, and a second layer comprises larger pores, or optionally an aforesaid gradient of pore size. The layers can subsequently have different pore sizes and gradients, particularly if there is a multitude of layers.
Exemplary Functionalization
According to an exemplary embodiment of the present invention, the porous compartments in the inorganic material, if present, or lumens present in the stent structure, can be used to incorporate beneficial agents. Incorporation of beneficial agents may be carried out by any suitable mean, preferably by dip-coating, spray coating or the like. The beneficial agent may be provided in an appropriate solvent, optionally using additives. The loading of these agents may be carried out under atmospheric, sub-atmospheric pressure or under vacuum. Alternatively, the exemplary loading may be carried out under high pressure. Incorporation of the beneficial agent may be carried out by applying electrical charge to the implant or exposing at least a portion of the implant to a gaseous material including the gaseous or vapor phase of the solvent in which an agent is dissolved or other gases that have a high degree of solubility in the loading solvent. In preferable embodiments, the beneficial agents are provided using carriers that are incorporated into the compartment of the implant. Carriers can be selected from any suitable group of polymers or solvents.
Preferable carriers are polymers like biocompatible polymers, for example. In specific embodiments it can be particularly preferable to select carriers from pH-sensitive polymers, like, for example, however not exclusively: poly(acrylic acid) and derivatives, for example: homopolymers like poly(amino carboxylic acid), poly(acrylic acid), poly(methyl acrylic acid) and their copolymers. This applies likewise for polysaccharides like celluloseacetatephthalate, hydroxylpropylmethylcellulose-phthalate, hydroxypropylmethylcellulosesuccinate, celluloseacetatetrimellitate and chitosan.
In certain exemplary embodiments, it can be preferable to select carriers from temperature sensitive polymers, like for example, however not exclusively: poly(N-isopropylacrylamide-co-sodium-acrylate-co-n-N-alkylacrylamide), poly(N-methyl-N-n-propylacrylamide), poly(N-methyl-N-isopropylacrylamide), poly(N-N-propylmethacrylamide), poly(N-isopropylacrylamide), poly(N,N-diethylacrylamide), poly(N-isopropylmethacrylamide), poly(N-cyclopropylacrylamide), poly(N-ethylacrylamide), poly(N-ethylmethylacrylamide), poly(N-methyl-N-ethylacrylamide), poly(N-cyclopropylacrylamide). Other polymers suitable to be used as a carrier with thermogel characteristics are hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, ethylhydroxyethylcellulose and pluronics like F-127, L-122, L-92, L-81, L-61. Preferable carrier polymers include also, however not exclusively, functionalized styrene, like amino styrene, functionalized dextrane and polyamino acids. Furthermore polyamino acids, (poly-D-amino acids as well as poly-L-amino acids), for example polylysine, and polymers which contain lysine or other suitable amino acids. Other useful polyamino acids are polyglutamic acids, polyaspartic acid, copolymers of lysine and glutamine or aspartic acid, copolymers of lysine with alanine, tyrosine, phenylalanine, serine, tryptophan and/or proline.
In an exemplary setup of a functionalization, a stent made of a substantially non-porous inorganic carbon material can be dipped into a drug solution made out of a about 5% paclitaxel in ethanol. After dipping the stent into the solution for about 5 minutes, the stent may be taken out, dried at room temperature in air and weighed. The increase of weight can be approximately 20 μg, visual inspection possibly revealing a paclitaxel crystalline top coat of the stent. When introducing this stent into an about 5 ml PBS buffer solution to measure the drug release from the surface for about 12 hours and measuring the paclitaxel concentration using standard HPLC methods, e.g., nearly 50% of paclitaxel can be eluted from the surface of the stent. Repeating the elution test, the sample may again be introduced into an about 5 ml PBS solution for about 12 hours and then removed. The measured drug concentration may indicate a release of approximately 40% of the remaining drug from the surface. In case of a stent made from a porous carbon material, e.g., only about 15% of paclitaxel may be eluted from the stent, and upon repeating the elution test, a release of approximately 10% of the remaining drug from the stent can be observed, demonstrating the retention of beneficial agent in the pore system of the stent. Using stent materials having smaller pore sizes, retention can be even more, thus allowing to tailor the release of beneficial agents by tailoring the pore size parameters.
Exemplary Beneficial Agents
Exemplary beneficial agents can be incorporated partially or completely into the compartment or reservoir of the implant. Furthermore, it is also one aspect of the present invention to optionally coat the exemplary implant with beneficial agents partially or completely.
Biologically, therapeutically or pharmaceutically active agents according to the present invention may be a drug, pro-drug or even a targeting group or a drug comprising a targeting group. The active agents may be in crystalline, polymorphous or amorphous form or any combination thereof in order to be used in the present invention.
Suitable therapeutically active agents may be selected from the group of enzyme inhibitors, hormones, cytokines, growth factors, receptor ligands, antibodies, antigens, ion binding agents, such as crown ethers and chelating compounds, substantial complementary nucleic acids, nucleic acid binding proteins including transcriptions factors, toxins etc. Examples of such active agents are, for example, cytokines, such as erythropoietine (EPO), thrombopoietine (TPO), interleukines (including IL-I to IL-17), insulin, insulin-like growth factors (including IGF-1 and IGF-2), epidermal growth factor (EGF), transforming growth factors (including TGF-alpha and TGF-beta), human growth hormone, transferrine, low density lipoproteins, high density lipoproteins, leptine, VEGF, PDGF, ciliary neurotrophic factor, prolactine, adrenocorticotropic hormone (ACTH), calcitonin, human chorionic gonadotropin, cortisol, estradiol, follicle stimulating hormone (FSH), thyroid-stimulating hormone (TSH), leutinizing hormone (LH), progesterone, testosterone, toxins including ricine and further active agents, such as those included in Physician's Desk Reference, 58th Edition, Medical Economics Data Production Company, Montvale, N.J., 2004 and the Merck Index, 13th Edition (particularly pages Ther-1 to Ther-29).
In an exemplary embodiment, the therapeutically active agent can be selected from the group of drugs for the therapy of oncological diseases and cellular or tissue alterations. Suitable therapeutic agents are, e.g., antineoplastic agents, including alkylating agents, such as alkyl sulfonates, e.g., busulfan, improsulfan, piposulfane, aziridines, such as benzodepa, carboquone, meturedepa, uredepa; ethyleneimine and methylmelamines, such as altretamine, triethylene melamine, triethylene phosphoramide, triethylene thiophosphoramide, trimethylolmelamine; so-called nitrogen mustards, such as chlorambucil, chlornaphazine, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethaminoxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitroso urea-compounds, such as carmustine, chlorozotocin, fotenmustine, lomustine, nimustine, ranimustine; dacarbazine, mannomustine, mitobranitol, mitolactol; pipobroman; doxorubicin and cis-platinum and its derivatives, etc., combinations and/or derivatives of any of the foregoing.
In a further exemplary embodiment, the therapeutically active agent can be selected from the group of anti-viral and anti-bacterial agents, such as aclacinomycin, actinomycin, anthramycin, azaserine, bleomycin, cuctinomycin, carubicin, carzinophilin, chromomycines, ductinomycin, daunorubicin, 6-diazo-5-oxn-1-norieucin, doxorubicin, epirubicin, mitomycins, mycophenolsaure, mogalumycin, olivomycin, peplomycin, plicamycin, porfiromycin, puromycin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, aminoglycosides or polyenes or macrolid-antibiotics, etc., combinations and/or derivatives of any of the foregoing.
In a further exemplary embodiment, the therapeutically active agent may include a radio-sensitizer drug, or a steroidal or non-steroidal anti-inflammatory drug.
In a further exemplary embodiment, the therapeutically active agent can be selected from agents referring to angiogenesis, such as e.g. endostatin, angiostatin, interferones, platelet factor 4 (PF4), thrombospondin, transforming growth factor beta, tissue inhibitors of the metalloproteinases-1, -2 and -3 (TIMP-1, -2 and -3), TNP-470, marimastat, neovastat, BMS-275291, COL-3, AG3340, thalidomide, squalamine, combrestastatin, SU5416, SU6668, IFN-[alpha], EMD121974, CAI, IL-12 and IM862 etc., combinations and/or derivatives of any of the foregoing.
In a further exemplary embodiment, the therapeutically-active agent may be selected from the group of nucleic acids, wherein the term nucleic acids also comprises oligonucleotides wherein at least two nucleotides are covalently linked to each other, for example in order to provide gene therapeutic or antisense effects. Nucleic acids preferably comprise phosphodiester bonds, which also comprise those which are analogues having different backbones. Analogues may also contain backbones, such as, for example, phosphoramide (Beaucage et al., Tetrahedron 49(10):1925 (1993) and the references cited therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805 (1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 91986)); phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S. Pat. No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111:2321 (1989), O-methylphosphoroamidit-compounds (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide-nucleic acid-backbones and their compounds (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl: 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207(1996), wherein these references are incorporated by reference herein further analogues are those having ionic backbones, see Denpcy et al., Proc. Natl. Acad. Sci. USA 92:6097 (1995), or non-ionic backbones, see U.S. Pat. Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Kiedrowshi et al., Angew. Chem. Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside & Nucleotide 13:1597 (1994); chapters 2 and 3, ASC Symposium Series 580, “Carbohydrate Modifications in Antisense Research”, Ed. Y. S. Sanghui and P. Dan Cook; Mesmaeker et al., Bioorganic & Medicinal Chem. Lett. 4:395 (1994); Jeffs et al., J. Biomolecular NMR 34:17 (1994); Tetrahedron Lett. 37:743 (1996), and non-ribose-backbones, including those which are described in U.S. Pat. Nos. 5,235,033 and 5,034,506, and in chapters 6 and 7 of ASC Symposium Series 580, “Carbohydrate Modifications in Antisense Research”, Ed. Y. S. Sanghui and P. Dan Cook. The nucleic acids having one or more carbocylic sugars are also suitable as nucleic acids for use in the present invention, see Jenkins et al., Chemical Society Review (1995), pages 169 to 176 as well as others which are described in Rawls, C & E News, 2 June 1997, page 36. Besides the selection of the nucleic acids and nucleic acid analogues known in the prior art, also a mixture of naturally occurring nucleic acids and nucleic acid analogues or mixtures of nucleic acid analogues may be used.
In a further exemplary embodiment, the therapeutically active agent is selected from the group of metal ion complexes, as described in International Applications PCT/US95/16377, PCT/US95/16377, PCT/US96/19900 and PCT/US96/15527, whereas such agents reduce or inactivate the bioactivity of their target molecules, preferably proteins, such as enzymes.
Therapeutically active agents may also include anti-migratory, anti-proliferative or immune-suppressive, anti-inflammatory or re-endotheliating agents, such as, e.g., everolimus, tacrolimus, sirolimus, mycofenolate-mofetil, rapamycin, paclitaxel, actinomycine D, angiopeptin, batimastate, estradiol, statines and others, their derivatives and analogues.
Active agents or combinations of active agents may further be selected from heparin, synthetic heparin analogs (e.g., fondaparinux), hirudin, antithrombin III, drotrecogin alpha; fibrinolytics, such as alteplase, plasmin, lysokinases, factor XIa, prourokinase, urokinase, anistreplase, streptokinase; platelet aggregation inhibitors, such as acetylsalicylic acid [aspirin], ticlopidine, clopidogrel, abciximab, dextrans; corticosteroids, such as alclometasone, amcinonide, augmented betamethasone, beclomethasone, betamethasone, budesonide, cortisone, clobetasol, clocortolone, desonide, desoximetasone, dexamethasone, fluocinolone, fluocinonide, flurandrenolide, flunisolide, fluticasone, halcinonide, halobetasol, hydrocortisone, methylprednisolone, mometasone, prednicarbate, prednisone, prednisolone, triamcinolone; so-called non-steroidal anti-inflammatory drugs (NSAIDs), such as diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, salsalate, sulindac, tolmetin, celecoxib, rofecoxib; cytostatics, such as alkaloides and podophyllum toxins, such as vinblastine, vincristine; alkylating agents, such as nitrosoureas, nitrogen lost analogs; cytotoxic antibiotics, such as daunorubicin, doxorubicin and other anthracyclines and related substances, bleomycin, mitomycin; antimetabolites, such as folic acid analogs, purine analogs or pyrimidine analogs; paclitaxel, docetaxel, sirolimus; platinum compounds, such as carboplatin, cisplatin or oxaliplatin; amsacrin, irinotecan, imatinib, topotecan, interferon-alpha 2a, interferon-alpha 2b, hydroxycarbamide, miltefosine, pentostatin, porfimer, aldesleukin, bexaroten, tretinoin; antiandrogens and antiestrogens; antiarrythmics in particular class I antiarrhythmic, such as antiarrhythmics of the quinidine type, quinidine, dysopyramide, ajmaline, prajmalium bitartrate, detajmium bitartrate; antiarrhythmics of the lidocaine type, e.g., lidocaine, mexiletin, phenytoin, tocainid; class Ic antiarrhythmics, e.g., propafenon, flecainid(acetate); class II antiarrhythmics beta-receptor blockers, such as metoprolol, esmolol, propranolol, metoprolol, atenolol, oxprenolol; class III antiarrhythmics, such as amiodarone, sotalol; class IV antiarrhythmics, such as diltiazem, verapamil, gallopamil; other antiarrhythmics, such as adenosine, orciprenaline, ipratropium bromide; agents for stimulating angiogenesis in the myocardium, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), non-viral DNA, viral DNA, endothelial growth factors: FGF-1, FGF-2, VEGF, TGF; antibiotics, monoclonal antibodies, anticalins; stem cells, endothelial progenitor cells (EPC); digitalis glycosides, such as acetyl digoxin/metildigoxin, digitoxin, digoxin; cardiac glycosides, such as ouabain, proscillaridin; antihypertensives, such as CNS active antiadrenergic substances, e.g., methyldopa, imidazoline receptor agonists; calcium channel blockers of the dihydropyridine type, such as nifedipine, nitrendipine; ACE inhibitors: quinaprilate, cilazapril, moexipril, trandolapril, spirapril, imidapril, trandolapril; angiotensin II antagonists: candesartancilexetil, valsartan, telmisartan, olmesartanmedoxomil, eprosartan; peripherally active alpha-receptor blockers, such as prazosin, urapidil, doxazosin, bunazosin, terazosin, indoramin; vasodilatators, such as dihydralazine, diisopropylamine dichloracetate, minoxidil, nitroprusside sodium; other antihypertensives, such as indapamide, co-dergocrine mesylate, dihydroergotoxin methanessulfonate, cicletanin, bosentan, fludrocortisone; phosphodiesterase inhibitors, such as milrinon, enoximon and antihypotensives, such as in particular adrenergic and dopaminergic substances, such as dobutamine, epinephrine, etilefrine, norfenefrine, norepinephrine, oxilofrine, dopamine, midodrine, pholedrine, ameziniummetil; and partial adrenoceptor agonists, such as dihydroergotamine; fibronectin, polylysine, ethylene vinyl acetate, inflammatory cytokines, such as: TGF, PDGF, VEGF, bFGF, TNF, NGF, GM-CSF, IGF-a, IL-1, IL 8, IL-6, growth hormone; as well as adhesive substances, such as cyanoacrylates, beryllium, silica; and growth factors, such as erythropoetin, hormones, such as corticotropins, gonadotropins, somatropins, thyrotrophins, desmopressin, terlipressin, pxytocin, cetrorelix, corticorelin, leuprorelin, triptorelin, gonadorelin, ganirelix, buserelin, nafarelin, goserelin, as well as regulatory peptides, such as somatostatin, octreotid; bone and cartilage stimulating peptides, bone morphogenetic proteins (BMPs), in particulary recombinant BMPs, such as recombinant human BMP-2 (rhBMP-2), bisphosphonate (e.g., risedronate, pamidronate, ibandronate, zoledronic acid, clodronsaiure, etidronsaure, alendronic acid, tiludronic acid), fluorides, such as disodium fluorophosphate, sodium fluoride; calcitonin, dihydrotachystyrol; growth factors and cytokines, such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factors (FGFs), transforming growth factors-b (TGFs-b), transforming growth factor-a (TGF-a), erythropoietin (EPO), insulin-like growth factor-I (IGF-I), insulin-like growth factor-II (IGF-II), interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-a (TNF-a), tumor necrosis factor-b (TNF-b), interferon-g (INF-g), colony stimulating factors (CSFs); monocyte chemotactic protein, fibroblast stimulating factor 1, histamine, fibrin or fibrinogen, endothelin-1, angiotensin II, collagens, bromocriptine, methysergide, methotrexate, carbon tetrachloride, thioacetamide and ethanol; as well as silver (ions), titanium dioxide, antibiotics and anti-infective drugs, such as in particular β-lactam antibiotics, e.g., β-lactamase-sensitive penicillins, such as benzyl penicillins (penicillin G), phenoxymethylpenicillin (penicillin V); β-lactamase-resistent penicillins, such as aminopenicillins, e.g., amoxicillin, ampicillin, bacampicillin; acylaminopenicillins, such as mezlocillin, piperacillin; carboxypenicillins, cephalosporins, such as cefazoline, cefuroxim, cefoxitin, cefotiam, cefaclor, cefadroxil, cefalexin, loracarbef, cefixim, cefuroximaxetil, ceftibuten, cefpodoximproxetil, cefpodoximproxetil; aztreonam, ertapenem, meropenem; β-lactamase inhibitors, such as sulbactam, sultamicillintosylate; tetracyclines, such as doxycycline, minocycline, tetracycline, chlorotetracycline, oxytetracycline; aminoglycosides, such as gentamicin, neomycin, streptomycin, tobramycin, amikacin, netilmicin, paromomycin, framycetin, spectinomycin; macrolide antibiotics, such as azithromycin, clarithromycin, erythromycin, roxithromycin, spiramycin, josamycin; lincosamides, such as clindamycin, lincomycin; gyrase inhibitors, such as fluoroquinolones, e.g., ciprofloxacin, ofloxacin, moxifloxacin, norfloxacin, gatifloxacin, enoxacin, fleroxacin, levofloxacin; quinolones, such as pipemidic acid; sulfonamides, trimethoprim, sulfadiazine, sulfalene; glycopeptide antibiotics, such as vancomycin, teicoplanin; polypeptide antibiotics, such as polymyxins, e.g., colistin, polymyxin-b, nitroimidazole derivates, e.g., metronidazole, tinidazole; aminoquinolones, such as chloroquin, mefloquin, hydroxychloroquin; biguanids, such as proguanil; quinine alkaloids and diaminopyrimidines, such as pyrimethamine; amphenicols, such as chloramphenicol; rifabutin, dapson, fusidic acid, fosfomycin, nifuratel, telithromycin, fusafungin, fosfomycin, pentamidine diisethionate, rifampicin, taurolidin, atovaquon, linezolid; virus static, such as aciclovir, ganciclovir, famciclovir, foscarnet, inosine-(dimepranol-4-acetamidobenzoate), valganciclovir, valaciclovir, cidofovir, brivudin; antiretroviral active ingredients (nucleoside analog reverse-transcriptase inhibitors and derivatives), such as lamivudine, zalcitabine, didanosine, zidovudin, tenofovir, stavudin, abacavir; non-nucleoside analog reverse-transcriptase inhibitors: amprenavir, indinavir, saquinavir, lopinavir, ritonavir, nelfinavir; amantadine, ribavirine, zanamivir, oseltamivir or lamivudine, as well as any combinations and mixtures thereof.
In an alternative exemplary embodiment of the present invention, the active agents can be encapsulated in polymers, vesicles, liposomes or micelles.
Suitable diagnostically active agents for use in an exemplary embodiment of the present invention can be, e.g., signal generating agents or materials, which may be used as markers. Such signal generating agents include materials which in physical, chemical and/or biological measurement and verification methods lead to detectable signals, for example in image-producing methods. It is not important for the present invention, whether the signal processing is carried out exclusively for diagnostic or therapeutic purposes. Typical imaging methods are for example radiographic methods, which are based on ionizing radiation, for example conventional X-ray methods and X-ray based split image methods, such as computer tomography, neutron transmission tomography, radiofrequency magnetization, such as magnetic resonance tomography, further by radionuclide-based methods, such as scintigraphy, Single Photon Emission Computed Tomography (SPECT), Positron Emission Computed Tomography (PET), ultrasound-based methods or fluoroscopic methods or luminescence or fluorescence based methods, such as Intravasal Fluorescence Spectroscopy, Raman spectroscopy, Fluorescence Emission Spectroscopy, Electrical Impedance Spectroscopy, colorimetry, optical coherence tomography, etc, further Electron Spin Resonance (ESR), Radio Frequency (RF) and Microwave Laser and similar methods.
Signal generating agents can be metal-based from the group of metals, metal oxides, metal carbides, metal nitrides, metal oxynitrides, metal carbonitrides, metal oxycarbides, metal oxynitrides, metal oxycarbonitrides, metal hydrides, metal alkoxides, metal halides, inorganic or organic metal salts, metal polymers, metallocenes, and other organometallic compounds.
Preferable metal-based agents are e.g. nanomorphous nanoparticles from metals, metal oxides semiconductors as defined above as the metal-based particles, or mixtures thereof. In this regard, it may be preferable to select at least a part of the metal-based particles from those materials capable of functioning as signal generating agents, for example to mark the implant for better visibility and localization in the body after implantation.
Further, signal producing metal-based agents can be selected from salts or metal ions, which preferably have paramagnetic properties, for example lead (II), bismuth (II), bismuth (III), chromium (III), manganese (II), manganese (III), iron (II), iron (III), cobalt (II), nickel (II), copper (II), praseodymium (III), neodymium (III), samarium (III), or ytterbium (III), holmium (III) or erbium (III) etc. Based on especially pronounced magnetic moments, especially gadolinium (III), terbium (III), dysprosium (III), holmium (III) and erbium (III) are mostly preferable. Further one can select from radioisotopes. Examples of a few applicable radioisotopes include H 3, Be 10, O 15, Ca 49, Fe 60, In 111, Pb 210, Ra 220, Ra 224 and the like. Typically such ions are present as chelates or complexes, wherein for example as chelating agents or ligands for lanthanides and paramagnetic ions compounds, such as diethylenetriamine pentaacetic acid (“DTPA”), ethylenediamine tetra acetic acid (“EDTA”), or tetraazacyclododecane-N,N′,N″,N′″-tetra acetic acid (“DOTA”) are used. Other typical organic complexing agents are for example published in Alexander, Chem. Rev. 95:273-342 (1995) and Jackels, Pharm. Med. Imag, Section III, Chap. 20, p 645 (1990). Other usable chelating agents may be found in U.S. Pat. Nos. 5,155,215; 5,087,440; 5,219,553; 5,188,816; 4,885,363; 5,358,704; 5,262,532, and Meyer et al., Invest. Radiol. 25: S53 (1990), further U.S. Pat Nos. 5,188,816, 5,358,704, 4,885,363, and 5,219,553. In addition, salts and chelates from the lanthanide group with the atomic numbers 57-83 or the transition metals with the atomic numbers 21-29, or 42 or 44 may be incorporated into the implants of exemplary embodiments of the present invention.
In addition suitable can be paramagnetic perfluoroalkyl containing compounds which for example are described in German Patent Application Nos. 196 03 0 33 and 197 29 013 and International Patent Publication WO 97/26017, further diamagnetic perfluoroalkyl containing substances of the general formula:
R<PF>−L<II>−G<III>,
whereas R<PF> represents a perfluoroalkyl group with 4 to 30 carbon atoms, L<II> stands for a linker and G<III> for a hydrophilic group. The linker L is a direct bond, an —SO2-group or a straight or branched carbon chain with up to 20 carbon atoms which can be substituted with one or more —OH, —COO<−>, —SO3-groups and/or if necessary one or more —O—, —S—, —CO—, —CONH—, —NHCO—, —CONR—, —NRCO—, —SO2-, —PO4-, —NH—, —NR-groups, an aryl ring or contain a piperazine, wherein R stands for a C1 to C20 alkyl group, which again can contain and/or have one or a plurality of O atoms and/or be substituted with —COO<−> or SO3-groups.
The hydrophilic group G<III> can be selected from a mono or disaccharide, one or a plurality of —COO<−> or —SO3<−>-groups, a dicarboxylic acid, an isophthalic acid, a picolinic acid, a benzenesulfonic acid, a tetrahydropyranedicarboxylic acid, a 2,6-pyridinedicarboxylic acid, a quaternary ammonium ion, an aminopolycarboxcylic acid, an aminodipolyethyleneglycol sulfonic acid, an aminopolyethyleneglycol group, an SO2-(CH2)2-OH-group, a polyhydroxyalkyl chain with at least two hydroxyl groups or one or a plurality of polyethylene glycol chains having at least two glycol units, wherein the polyethylene glycol chains are terminated by an —OH or —OCH3-group, or similar linkages.
In exemplary embodiments, paramagnetic metals in the form of metal complexes with phthalocyanines may be used to functionalize the implant, especially as described in Phthalocyanine Properties and Applications, Vol. 14, C. C. Leznoff and A. B. P. Lever, VCH Ed. Examples are octa(1,4,7,10-tetraoxaundecyl)Gd-phthalocyanine, octa(1,4,7,10-tetraoxaundecyl)Gd-phthalocyanine, octa(1,4,7,10-tetraoxaundecyl)Mn-phthalocyanine, octa(1,4,7,10-tetraoxaundecyl)Mn-phthalocyanine, as described in U.S. Patent Publication No. 2004/214810.
Super-paramagnetic, ferromagnetic or ferrimagnetic signal generating agents may also be used. For example among magnetic metals, alloys are preferable, among ferrites, such as gamma iron oxide, magnetites or cobalt-, nickel- or manganese-ferrites, corresponding agents are preferably selected, especially particles as described in International Patent Publications WO83/03920, WO83/01738, WO85/02772 and WO89/03675, in U.S. Pat. Nos. 4,452,773 and 4,675,173, in International Patent Publication WO88/00060 as well as U.S. Pat. No. 4,770,183, in International Patent Publication WO90/01295 and in International Patent Publication WO90/01899.
Further, magnetic, paramagnetic, diamagnetic or super paramagnetic metal oxide crystals having diameters of less than about 4000 Angstroms are especially preferable as degradable non-organic diagnostic agents. Suitable metal oxides can be selected from iron oxide, cobalt oxides, iridium oxides or the like, which provide suitable signal producing properties and which have especially biocompatible properties or are biodegradable. Crystalline agents of this group having diameters smaller than 500 Angstroms may be used. These crystals can be associated covalently or non-covalently with macromolecular species. Further, zeolite containing paramagnets and gadolinium containing nanoparticles can be selected from polyoxometallates, preferably of the lanthanides, (e.g., K9GdW10O36).
For optimizing the image producing properties the average particle size of the magnetic signal producing agents may be limited to 5 μm at maximum, such as from about 2 nm up to 1 μm, e.g. from about 5 nm to 200 nm. The super paramagnetic signal producing agents can be chosen for example from the group of so-called SPIOs (super paramagnetic iron oxides) with a particle size larger than about 50 nm or from the group of the USPIOs (ultra small super paramagnetic iron oxides) with particle sizes smaller than 50 nm.
Signal generating agents for imparting further functionality to the implants of embodiments of the present invention can further be selected from endohedral fullerenes, as disclosed for example in U.S. Pat. No. 5,688,486 or International Patent Publication WO 93/15768, or from fullerene derivatives and their metal complexes, such as fullerene species, which comprise carbon clusters having 60, 70, 76, 78, 82, 84, 90, 96 or more carbon atoms. An overview of such species can be gathered from European patent application No. 1331226A2. Metal fullerenes or endohedral carbon-carbon nanoparticles with arbitrary metal-based components can also be selected. Such endohedral fullerenes or endometallo fullerenes may contain for example rare earths, such as cerium, neodymium, samarium, europium, gadolinium, terbium, dysprosium or holmium. The choice of nanomorphous carbon species is not limited to fullerenes, other nanomorphous carbon species, such as nanotubes, onions, etc. may also be applicable.
In another exemplary embodiment fullerene species may be selected from non-endohedral or endohedral forms which contain halogenated, preferably iodated, groups, as described in U.S. Pat. No. 6,660,248.
Generally, mixtures of such signal generating agents of different specifications can also used, depending on the desired properties of the signal generating material properties. The signal producing agents used can have a size of about 0.5 nm to 1,000 nm, preferably about 0.5 nm to 900 nm, especially preferable from about 0.7 to 100 nm, and the may partly replace the metal-based particles. Nanoparticles are easily modifiable based on their large surface to volume ratios. The nanoparticles can for example be modified non-covalently by means of hydrophobic ligands, for example with trioctylphosphine, or be covalently modified. Examples of covalent ligands are thiol fatty acids, amino fatty acids, fatty acid alcohols, fatty acids, fatty acid ester groups or mixtures thereof, for example oleic acid and oleylamine.
In exemplary embodiments of the present invention, the active ingredients, such as signal producing agents can be encapsulated in micelles or liposomes with the use of amphiphilic components, or may be encapsulated in polymeric shells, wherein the micelles/liposomes can have a diameter of about 2 nm to 800 nm, preferably from about 5 to 200 nm, especially preferable from about 10 to 25 nm. The micelles/liposomes may be added to the suspension before molding, to be incorporated into the implant. The size of the micelles/liposomes is, without committing to a specific theory, dependant on the number of hydrophobic and hydrophilic groups, the molecular weight of the nanoparticles and the aggregation number. In aqueous solutions the use of branched or unbranched amphiphilic substances, is especially preferable in order to achieve the encapsulation of signal generating agents in liposomes/micelles. The hydrophobic nucleus of the micelles hereby contains in a exemplary embodiment a multiplicity of hydrophobic groups, preferably between 1 and 200, especially preferable between about 1 and 100 and mostly preferable between about 1 and 30 according to the desired setting of the micelle size.
Such signal generating agents encapsulated in micelles and incorporated into the porous implant can moreover be functionalized, while linker (groups) are attached at any desired position, preferably amino-, thiol, carboxyl-, hydroxyl-, succinimidyl, maleimidyl, biotin, aldehyde- or nitrilotriacetate groups, to which any desired corresponding chemically covalent or non-covalent other molecules or compositions can be bound according to the prior art. Here, especially biological molecules, such as proteins, peptides, amino acids, polypeptides, lipoproteins, glycosaminoglycanes, DNA, RNA or similar biomolecules are preferable especially.
Signal generating agents may also be selected from non-metal-based signal generating agents, for example from the group of X-ray contrast agents, which can be ionic or non-ionic. Among the ionic contrast agents are included salts of 3-acetyl amino-2,4-6-triiodobenzoic acid, 3,5-diacetamido-2,4,6-triiodobenzoic acid, 2,4,6-triiodo-3,5-dipropionamido-benzoic acid, 3-acetyl amino-5-((acetyl amino)methyl)-2,4,6-triiodobenzoic acid, 3-acetyl amino-5-(acetyl methyl amino)-2,4,6-triiodobenzoic acid, 5-acetamido-2,4,6-triiodo-N-((methylcarbamoyl)methyl)-isophthalamic acid, 5-(2-methoxyacetamido)-2,4,6-triiodo-N-[2-hydroxy-1-(methylcarbamoyl)-ethoxy 1]-isophthalamic acid, 5-acetamido-2,4,6-triiodo-N-methylisophthalamic acid, 5-acetamido-2,4,6-triiodo-N-(2-hydroxyethyl)-isophthalamic acid 2-[[2,4,6-triiodo-3[(1-oxobutyl)-amino]phenyl]methyl]-butanoic acid, beta-(3-amino-2,4,6-triiodophenyl)-alpha-ethyl-propanoic acid, 3-ethyl-3-hydroxy-2,4,6-triiodophenyl-propanoic acid, 3-[[(dimethylamino)-methyl]amino]-2,4,6-triiodophenyl-propanoic acid (see Chem. Ber. 93: 2347 (1960)), alpha-ethyl-(2,4,6-triiodo-3-(2-oxo-1-pyrrolidinyl)-phenyl)-propanoic acid, 2-[2-[3-(acetyl amino)-2,4,6-triiodophenoxy]ethoxymethyl]butanoic acid, N-(3-amino-2,4,6-triiodobenzoyl)-N-phenyl-.beta.-aminopropanoic acid, 3-acetyl-[(3-amino-2,4,6-triiodophenyl)amino]-2-methylpropanoic acid, 5-[(3-amino-2,4,6-triiodophenyl)methyl amino]-5-oxypentanoic acid, 4-[ethyl-[2,4,6-triiodo-3-(methyl amino)-phenyl]amino]-4-oxo-butanoic acid, 3,3′-oxy-bis[2,1-ethanediyloxy-(1-oxo-2,1-ethanediyl)imino]bis-2,4,6-triiodobenzoic acid, 4,7,10,13-tetraoxahexadecane-1,16-dioyl-bis(3-carboxy-2,4,6-triiodoanilide), 5,5′-(azelaoyldiimino)-bis[2,4,6-triiodo-3-(acetyl amino)methyl-benzoic acid], 5,5′-(apidoldiimino)bis(2,4,6-triiodo-N-methyl-isophthalamic acid), 5,5′-(sebacoyl-diimino)-bis(2,4,6-triiodo-N-methylisophthalamic acid), 5,5-[N,N-diacetyl-(4,9-dioxy-2,11-dihydroxy-1,12-dodecanediyl)diimino]bis(2,4,6-triiodo-N-methyl-isophthalamic acid), 5,5′5″-(nitrilo-triacetyltriimino)tris(2,4,6-triiodo-N-methyl-isophthalamic acid), 4-hydroxy-3,5-diiodo-alpha-phenylbenzenepropanoic acid, 3,5-diiodo-4-oxo-1(4H)-pyridine acetic acid, 1,4-dihydro-3,5-diiodo-1-methyl-4-oxo-2,6-pyridinedicarboxylic acid, 5-iodo-2-oxo-1(2H)-pyridine acetic acid, and N-(2-hydroxyethyl)-2,4,6-triiodo-5-[2,4,6-triiodo-3-(N-methylacetamido)-5-(methylcarbomoyl)benzamino]acetamido]-isophthalamic acid, and the like, especially preferable, as well as other ionic X-ray contrast agents suggested in the literature, for example in J. Am. Pharm. Assoc., Sci. Ed. 42:721 (1953), Swiss Patent 480071, JACS 78:3210 (1956), German patent 2229360, U.S. Pat. No. 3,476,802, Arch. Pharm. (Weinheim, Germany) 306: 11 834 (1973), J. Med. Chem. 6: 24 (1963), FR-M-6777, Pharmazie 16: 389 (1961), U.S. Pat. Nos. 2,705,726 and 2,895,988, Chem. Ber. 93:2347(1960), SA-A-68/01614, Acta Radiol. 12: 882 (1972), British Patent No. 870321, Rec. Trav. Chim. 87: 308(1968), East German Patent No. 67209, German Patent No. 2050217, German Patent 2405652, Farm Ed. Sci. 28: 912(1973), Farm Ed. Sci. 28: 996 (1973), J. Med. Chem. 9: 964 (1966), Arzheim.-Forsch 14: 451 (1964), SE-A-344166, British Patent No. 1346796, U.S. Pat. Nos. 2,551,696 and 1,993,039, Ann 494: 284 (1932), J. Pharm. Soc. (Japan) 50: 727 (1930), and U.S. Pat. No. 4,005,188.
Examples of applicable non-ionic X-ray contrast agents in accordance with the present invention are metrizamide as described in German DE-A-2031724, iopamidol as described in BE-A-836355, iohexol as disclosed in British GB-A-1548594, iotrolan as described in European EP-A-33426, iodecimol as described in European EP-A-49745, iodixanol as in EP-A-108638, ioglucol as described in U.S. Pat. No. 4,314,055, ioglucomide as described in BE-A-846657, ioglunioe as in German DE-A-2456685, iogulamide as in BE-A-882309, iomeprol as in European EP-A-26281, iopentol as EP-A-105752, iopromide as in German DE-A-2909439, iosarcol as in German DE-A-3407473, iosimide as in German DE-A-3001292, iotasul as in European EP-A-22056, iovarsul as disclosed in European EP-A-83964 or ioxilan in International Publication WO87/00757.
Agents based on nanoparticle signal generating agents may be selected to impart functionality to the implant, which after release into tissues and cells are incorporated or are enriched in intermediate cell compartments and/or have an especially long residence time in the organism.
Such particles can include water-insoluble agents, a heavy element, such as iodine or barium, PH-50 as monomer, oligomer or polymer (iodinated aroyloxy ester having the empirical formula C19H23I3N2O6, and the chemical names 6-ethoxy-6-oxohexy-3,5-bis (acetyl amino)-2,4,6-triiodobenzoate), an ester of diatrizoic acid, an iodinated aroyloxy ester, or combinations thereof. Particle sizes which can be incorporated by macrophages may be preferable. A corresponding method for this is described in International Publication WO03/039601 and suitable agents are disclosed in the publications U.S. Pat. Nos. 5,322,679, 5,466,440, 5,518,187, 5,580,579, and 5,718,388. Nanoparticles which are marked with signal generating agents or such signal generating agents, such as PH-50, which accumulate in intercellular spaces and can make interstitial as well as extrastitial compartments visible, can be advantageous.
Signal generating agents may also include anionic or cationic lipids, as disclosed in U.S. Pat. No. 6,808,720, for example, anionic lipids, such as phosphatidyl acid, phosphatidyl glycerol and their fatty acid esters, or amides of phosphatidyl ethanolamine, such as anandamide and methanandamide, phosphatidyl serine, phosphatidyl inositol and their fatty acid esters, cardiolipin, phosphatidyl ethylene glycol, acid lysolipids, palmitic acid, stearic acid, arachidonic acid, oleic acid, linoleic acid, linolenic acid, myristic acid, sulfolipids and sulfatides, free fatty acids, both saturated and unsaturated and their negatively charged derivatives, etc. Moreover, halogenated, in particular fluorinated anionic lipids can be preferable in exemplary embodiments. The anionic lipids preferably contain cations from the alkaline earth metals beryllium (Be<+2>), magnesium (Mg<+2>), calcium (Ca<+2>), strontium (Sr<+2>) and barium (Ba<+2>), or amphoteric ions, such as aluminum (Al<+3>), gallium (Ga<+3>), germanium (Ge<+3>), tin (Sn+<4>) or lead (Pb<+2> and Pb<+4>), or transition metals, such as titanium (Ti<+3> and Ti<+4>), vanadium (V<+2> and V<+3>), chromium (Cr<+2> and Cr<+3>), manganese (Mn<+2> and Mn<+3>), iron (Fe<+2> and Fe<+3>), cobalt (Co<+2> and Co<+3>), nickel (Ni<+2> and Ni<+3>), copper (Cu<+2>), zinc (Zn<+2>), zirconium (Zr<+4>), niobium (Nb<+3>), molybdenum (Mo<+2> and Mo<+3>), cadmium (Cd<+2>), indium (In<+3>), tungsten (W<+2>and W<+4>), osmium (Os<+2>, Os<+3> and Os<+4>), iridium (Ir<+2>, Ir<+3> and Ir<+4>), mercury (Hg<+2>) or bismuth (Bi<+3>), and/or rare earths, such as lanthanides, for example lanthanum (La<+3>) and gadolinium (Gd<+3>). Cations can include calcium (Ca<+2>), magnesium (Mg<+2>) and zinc (Zn<+2>) and paramagnetic cations, such as manganese (Mn<+2>) or gadolinium (Gd<+3>).
Cationic lipids may include phosphatidyl ethanolamine, phospatidylcholine, Glycero-3-ethylphosphatidylcholine and their fatty acid esters, di- and tri-methylammoniumpropane, di- and tri-ethylammoniumpropane and their fatty acid esters, and also derivatives, such as N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (“DOTMA”); furthermore, synthetic cationic lipids based on for example naturally occurring lipids, such as dimethyldioctadecylammonium bromide, sphingolipids, sphingomyelin, lysolipids, glycolipids, such as for example gangliosides GM1, sulfatides, glycosphingolipids, cholesterol and cholesterol esters or salts, N-succinyldioleoylphosphattidyl ethanolamine, 1,2,-dioleoyl-sn-glycerol, 1,3-dipalmitoyl-2-succinylglycerol, 1,2-dipalmitoyl-sn-3-succinylglycerol, 1-hexadecyl-2-palmitoylglycerophosphatidyl ethanolamine and palmitoyl-homocystein, and fluorinated, derivatized cationic lipids, as disclosed in U.S. Ser. No. 08/391,938. Such lipids are furthermore suitable as components of signal generating liposomes, which especially can have pH-sensitive properties as disclosed in U.S. Patent Publication No. 2004/197392 and incorporated herein explicitly.
Signal generating agents may also include so-called micro bubbles or micro balloons, which contain stable dispersions or suspensions in a liquid carrier substance. Suitable gases may include air, nitrogen, carbon dioxide, hydrogen or noble gases, such as helium, argon, xenon or krypton, or sulfur-containing fluorinated gases, such as sulfur hexafluoride, disulfurdecafluoride or trifluoromethylsulfurpentafluoride, or for example selenium hexafluoride, or halogenated silanes, such as methylsilane or dimethylsilane, further short chain hydrocarbons, such as alkanes, specifically methane, ethane, propane, butane or pentane, or cycloalkanes, such as cyclopropane, cyclobutane or cyclopentane, also alkenes, such as ethylene, propene, propadiene or butene, or also alkynes, such as acetylene or propyne. Further ethers, such as dimethylether may be selected, or ketones, or esters or halogenated short-chain hydrocarbons or any desired mixtures of the above. Examples further include halogenated or fluorinated hydrocarbon gases, such as bromochlorodifluoromethane, chlorodifluoromethane, dichlorodifluoromethan, bromotrifluoromethane, chlorotrifluoromethane, chloropentafluoroethane, dichlorotetrafluoroethane, chlorotrifluoroethylene, fluoroethylene, ethyl fluoride, 1,1-difluoroethane or perfluorohydrocarbons, such as for example perfluoroalkanes, perfluorocycloalkanes, perfluoroalkenes or perfluorinated alkynes. Especially preferable are emulsions of liquid dodecafluoropentane or decafluorobutane and sorbitol, or similar, as disclosed in International Publication WO-A-93/05819.
Preferably such micro bubbles are selected, which are encapsulated in compounds having the structure R1-X-Z; R2-X-Z; or R3-X-Z′ whereas R1, R2 comprises and R3 hydrophobic groups selected from straight chain alkylenes, alkyl ethers, alkyl thiolethers, alkyl disulfides, polyfluoroalkylenes and polyfluoroalkylethers, Z comprises a polar group from CO2-M<+>, SO3<−>M<+>, SO4<−>M<+>, PO3<−>M<+>, PO4<−>M<+>2, N(R)4<+> or a pyridine or substituted pyridine, and a zwitterionic group, and finally X represents a linker which binds the polar group with the residues.
Gas-filled or in situ out-gassing micro spheres having a size of less than about 1000 μm can be further selected from biocompatible synthetic polymers or copolymers which comprise monomers, dimers or oligomers or other pre-polymer to pre-stages of the following polymerizable substances: acrylic acid, methacrylic acid, ethyleneimine, crotonic acid, acryl amide, ethyl acrylate, methylmethacrylate, 2-hydroxyethylmethacrylate (HEMA), lactonic acid, glycolic acid, [epsilon]caprolactone, acrolein, cyanoacrylate, bisphenol A, epichlorhydrin, hydroxyalkylacrylate, siloxane, dimethylsiloxane, ethylene oxide, ethylene glycol, hydroxyalkylmethacrylate, N-substituted acryl amide, N-substituted methacrylamides, N-vinyl-2-pyrrolidone, 2,4-pentadiene-1-ol, vinyl acetate, acrylonitrile, styrene, p-aminostyrene, p-aminobenzylstyrene, sodium styrenesulfonate, sodium-2-sulfoxyethylmethacrylate, vinyl pyridine, aminoethylmethacrylate, 2-methacryloyloxytrimethylammonium chloride, and polyvinylidenes, such as polyfunctional cross-linkable monomers, such as for example N,N′-methylene-bis-acrylamide, ethylene glycol dimethacrylate, 2,2′-(p-phenylenedioxy)-diethyldimethacrylate, divinylbenzene, triallylamine and methylene-bis-(4-phenyl-isocyanate), including any desired combinations thereof. Preferable polymers contain polyacrylic acid, polyethyleneimine, polymethacrylic acid, polymethylmethacrylate, polysiloxane, polydimethylsiloxane, polylactonic acid, poly([epsilon]-caprolactone), epoxy resins, poly(ethylene oxide), poly(ethylene glycol), and polyamides (e.g. Nylon) and the like, or any arbitrary mixtures thereof. Preferable copolymers contain among others polyvinylidene-polyacrylonitrile, polyvinylidene-polyacrylonitrile-polymethylmethacrylate, and polystyrene-polyacrylonitrile and the like, or any desired mixtures thereof. Methods for manufacture of such micro spheres are published for example in U.S. Pat. Nos. 4,179,546, 3,945,956 and 4,108,806, Japan Kokai Tokkyo Koho 62 286534, British Patent No. 1,044,680, U.S. Pat. Nos. 3,293,114, 3,401,475, 3,479,811, 3,488,714, 3,615,972, 4,549,892, 4,540,629, 4,421,562, 4,420,442, 4,898,734, 4,822,534, 3,732,172, 3,594,326, 3,015,128, Deasy, Microencapsulation and Related Drug Processes, Vol. 20, Chapters. 9 and 10, pp. 195-240 (Marcel Dekker, Inc., N.Y., 1984), Chang et al., Canadian J of Physiology and Pharmacology, Vol. 44, pp. 115-129 (1966), and Chang, Science, Vol. 146, pp. 524-525 (1964).
Other signal generating agents can be selected from agents, which are transformed into signal generating agents in organisms using in-vitro or in-vivo cells, cells as a component of cell cultures, of in-vitro tissues, or cells as a component of multicellular organisms, such as, for example, fungi, plants or animals, in exemplary embodiments from mammals, such as mice or humans. Such agents can be made available in the form of vectors for the transfection of multicellular organisms, wherein the vectors contain recombinant nucleic acids for the coding of signal generating agents. In exemplary embodiments this may be done with signal generating agents, such as metal binding proteins. It can be preferable to choose such vectors from the group of viruses for example from adeno viruses, adeno virus associated viruses, herpes simplex viruses, retroviruses, alpha viruses, pox viruses, arena-viruses, vaccinia viruses, influenza viruses, polio viruses or hybrids of any of the above.
Such signal generating agents may be used in combination with delivery systems, e.g. in order to incorporate nucleic acids, which are suitable for coding for signal generating agents, into the target structure. Virus particles for the transfection of mammalian cells may be used, wherein the virus particle contains one or a plurality of coding sequence/s for one or a plurality of signal generating agents as described above. In these cases the particles can be generated from one or a plurality of the following viruses: adeno viruses, adeno virus associated viruses, herpes simplex viruses, retroviruses, alpha viruses, pox viruses, arena-viruses, vaccinia viruses, influenza viruses and polio viruses.
These signal generating agents can be made available from colloidal suspensions or emulsions, which are suitable to transfect cells, preferably mammalian cells, wherein these colloidal suspensions and emulsions contain those nucleic acids which possess one or a plurality of the coding sequence(s) for signal generating agents. Such colloidal suspensions or emulsions can include macromolecular complexes, nano capsules, micro spheres, beads, micelles, oil-in-water- or water-in-oil emulsions, mixed micelles and liposomes or any desired mixture of the above.
In addition, cells, cell cultures, organized cell cultures, tissues, organs of desired species and non-human organisms can be chosen which contain recombinant nucleic acids having coding sequences for signal generating agents. In exemplary embodiments organisms can include mouse, rat, dog, monkey, pig, fruit fly, nematode worms, fish or plants or fungi. Further, cells, cell cultures, organized cell cultures, tissues, organs of desired species and non-human organisms can contain one or a plurality of vectors as described above.
Signal generating agents can be produced in vivo from proteins and made available as described above. Such agents can be directly or indirectly signal producing, while the cells produce (direct) a signal producing protein through transfection, or produce a protein which induces (indirect) the production of a signal producing protein. These signal generating agents are, e.g., detectable in methods, such as MRI while the relaxation times T1, T2, or both are altered and lead to signal producing effects which can be processed sufficiently for imaging. Such proteins can include protein complexes, such as metalloprotein complexes. Direct signal producing proteins can include such metalloprotein complexes which are formed in the cells. Indirect signal producing agents can include proteins or nucleic acids, for example, which regulate the homeostasis of iron metabolism, the expression of endogenous genes for the production of signal generating agents, and/or the activity of endogenous proteins with direct signal generating properties, for example Iron Regulatory Protein (IRP), transferrin receptor (for the take-up of Fe), erythroid-5-aminobevulinate synthase (for the utilization of Fe, H-Ferritin and L-Ferritin for the purpose of Fe storage). In exemplary embodiments both types of signal generating agents, that is direct and indirect, may be combined with each other, for example an indirect signal generating agent, which regulates the iron-homeostasis and a direct agent, which represents a metal binding protein.
In certain exemplary embodiments, where metal-binding polypeptides are selected as indirect agents, it can be advantageous if the polypeptide binds to one or a plurality of metals which possess signal generating properties. Metals with unpaired electrons in the Dorf orbitals may be used, such as for example Fe, Co, Mn, Ni, Gd etc., wherein especially Fe is available in high physiological concentrations in organisms. Such agents may form metal-rich aggregates, for example crystalline aggregates, whose diameters are larger than about 10 picometers, preferably larger than about 100 picometers, 1 nm, 10 nm or even further preferable larger than about 100 nm.
In addition, metal-binding compounds, which have sub-nanomolar affinities with dissociation constants of less than about 10-15 M, 10-2 M or smaller may be used to impart functionality for the implant. Typical polypeptides or metal-binding proteins are lactoferrin, ferritin, or other dimetallocarboxylate proteins, or so-called metal catcher with siderophoric groups, such as hemoglobin. A possible method for preparation of such signal generating agents, their selection and the possible direct or indirect agents which are producible in vivo and are suitable as signal generating agents is described in International Publication WO 03/075747.
Another group of signal generating agents can be photo physically signal producing agents which consist of dyestuff-peptide-conjugates. Such dyestuff-peptide-conjugates can provide a wide spectrum of absorption maxima, for example polymethin dyestuffs, such as cyanine-, merocyanine-, oxonol- and squarilium dyestuffs. From the class of the polymethin dyestuffs the cyanine dyestuffs, e.g. the indole structure based indocarbo-, indodicarbo- and indotricarbocyanines, can be suitable. Such dyestuffs can be substituted with suitable linking agents and can be functionalized with other groups as desired, see also German Patent Application No. 19917713.
The signal generating agents can further be functionalized as desired. The functionalization by means of so-called “Targeting” groups is meant to include functional chemical compounds which link the signal generating agent or its specifically available form (encapsulation, micelles, micro spheres, vectors etc.) to a specific functional location, or to a determined cell type, tissue type or other desired target structures. Targeting groups can permit the accumulation of signal-producing agents in or at specific target structures. Therefore, the targeting groups can be selected from such substances, which are principally suitable to provide a purposeful enrichment of the signal generating agents in their specifically available form by physical, chemical or biological routes or combinations thereof. Useful targeting groups can therefore include antibodies, cell receptor ligands, hormones, lipids, sugars, dextrane, alcohols, bile acids, fatty acids, amino acids, peptides and nucleic acids, which can be chemically or physically attached to signal-generating agents, in order to link the signal-generating agents into/onto a specifically desired structure. Exemplary targeting groups may include those which enrich signal-generating agents in/on a tissue type or on surfaces of cells. Here may not be necessary for the function, that the signal generating agent be taken up into the cytoplasm of the cells. Peptides can be targeting groups, for example chemotactic peptides that are used to visualize inflammation reactions in tissues by means of signal generating agents; see also International Publication WO 97/14443.
Antibodies can be used, including antibody fragments, Fab, Fab2, Single Chain Antibodies (for example Fv), chimerical antibodies, moreover antibody-like substances, for example so-called anticalines, wherein it may not be important whether the antibodies are modified after preparation, recombinants are produced or whether they are human or non-human antibodies. Humanized or human antibodies may be used, such as chimerical immunoglobulines, immunoglobulin chains or fragments (such as Fv, Fab, Fab′, F(ab″)2 or other antigen-binding subsequences of antibodies, which may partly contain sequences of non-human antibodies; humanized antibodies may include human immunoglobulines (receptor or recipient antibody), in which groups of a CDR (Complementary Determining Region) of the receptor are replaced through groups of a CDR of a non-human (spender or donor antibody), wherein the spender species for example, mouse, rabbit or other has appropriate specificity, affinity, and capacity for the binding of target antigens. In a few forms the Fv framework groups of the human immunglobulines are replaced by means of corresponding non-human groups. Humanized antibodies can moreover contain groups which either do not occur in either the CDR or Fv framework sequence of the spender or the recipient. Humanized antibodies essentially comprise substantially at least one or preferably two variable domains, in which all or substantial components of the CDR components of the CDR regions or Fv framework sequences correspond with those of the non-human immunoglobulin, and all or substantial components of the FR regions correspond with a human consensus-sequence. Targeting groups can also include hetero-conjugated antibodies. The functions of the selected antibodies or peptides include cell surface markers or molecules, particularly of cancer cells, wherein here a large number of known surface structures are known, such as HER2, VEGF, CA15-3, CA 549, CA 27.29, CA 19, CA 50, CA242, MCA, CA125, DE-PAN-2, etc.
Moreover, targeting groups may contain the functional binding sites of ligands and which are suitable for binding to any desired cell receptors. Examples of target receptors include receptors of the group of insulin receptors, insulin-like growth factor receptor (e IGF-1 and IGF-2), growth hormone receptor, glucose transporters (particularly GLUT 4 receptor), transferrin receptor (transferrin), Epidermal Growth Factor receptor (EGF), low density lipoprotein receptor, high density lipoprotein receptor, leptin receptor, estrogen receptor; interleukin receptors including IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, IL-13, IL-15, and IL-17 receptor, VEGF receptor (VEGF), PDGF receptor (PDGF), Transforming Growth Factor receptor (including TGF-[alpha] and TGF-[beta]), EPO receptor (EPO), TPO receptor (TPO), ciliary neurotrophic factor receptor, prolactin receptor, and T-cell receptors.
In addition, hormone receptors may be used, especially for hormones, such as steroidal hormones or protein- or peptide-based hormones, for example, epinephrines, thyroxines, oxytocine, insulin, thyroid-stimulating hormone, calcitonine, chorionic gonadotropine, corticotropine, follicle stimulating hormone, glucagons, leuteinizing hormone, lipotropine, melanocyte-stimulating hormone, norepinephrines, parathyroid hormone, Thyroid-Stimulating Hormone (TSH), vasopressin's, encephalin, serotonin, estradiol, progesterone, testosterone, cortisone, and glucocorticoide. Receptor ligands include those which are on the cell surface receptors of hormones, lipids, proteins, glycol proteins, signal transducers, growth factors, cytokine, and other bio molecules. Moreover, targeting groups can be selected from carbohydrates with the general formula: Cx(H2O)y, wherein herewith also monosaccharides, disaccharides and oligo—as well as polysaccharides are included, as well as other polymers which consist of sugar molecules which contain glycosidic bonds. Carbohydrates may include those in which all or parts of the carbohydrate components contain glycosylated proteins, including the monomers and oligomers of galactose, mannose, fructose, galactosamine, glucosamine, glucose, sialic acid, and the glycosylated components, which make possible the binding to specific receptors, especially cell surface receptors. Other useful carbohydrates include monomers and polymers of glucose, ribose, lactose, raffinose, fructose and other biologically occurring carbohydrates especially polysaccharides, for example, arabinogalactan, gum Arabica, mannan etc., which are suitable for introducing signal generating agents into cells, see U.S. Pat. No. 5,554,386.
Furthermore, targeting groups can include lipids, fats, fatty oils, waxes, phospholipids, glycolipids, terpenes, fatty acids and glycerides, and triglycerides, or eicosanoides, steroids, sterols, suitable compounds of which can also be hormones, such as prostaglandins, opiates and cholesterol etc. All functional groups can be selected as the targeting group, which possess inhibiting properties, such as for example enzyme inhibitors, preferably those which link signal generating agents into/onto enzymes.
Targeting groups can also include functional compounds which enable internalization or incorporation of signal generating agents in the cells, especially in the cytoplasm or in specific cell compartments or organelles, such as, for example, the cell nucleus. For example, such a targeting group may contains all or parts of HIV-1 that-proteins, their analogs and derivatized or functionally similar proteins, and in this way allows an especially rapid uptake of substances into the cells. As an example, refer to Fawell et al., PNAS USA 91:664(1994); Frankel et al., Cell 55:1189,(1988); Savionetal., J. Biol. Chem. 256:1149 (1981); Derossi et al., J. Biol. Chem. 269:10444 (1994); and Baldin et al., EMBO J. 9:1511 (1990).
Targeting groups can further include the so-called Nuclear Localisation Signal (NLS), which include positively charged (basic) domains which bind to specifically targeted structures of cell nuclei. Numerous NLS and their amino acid sequences are known including single basic NLS such as that of the SV40 (monkey virus) large T Antigen (pro Lys Lys Lys Arg Lys Val), Kalderon (1984), et al., Cell, 39:499-509), the teinoic acid receptor-[beta] nuclear localization signal (ARRRRP); NFKB p50 (EEVQRKRQKL; Ghosh et al., Cell 62:1019 (1990); NFKB p65 (EEKRKRTYE; Nolan et al., Cell 64:961 (1991), as well as others (see for example Boulikas, J. Cell. Biochem. 55(1):32-58 (1994), and double basic NLS's, such as for example xenopus (African clawed toad) proteins, nucleoplasmin (Ala Val Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys Leu Asp), Dingwall, et al., Cell, 30:449-458, 1982 and Dingwall, et al., J. Cell Biol., 107:641-849, 1988. Numerous localization studies have shown that NLSs, which are built into synthetic peptides which normally do not address the cell nucleus or were coupled to reporter proteins, lead to an enrichment of such proteins and peptides in cell nuclei. Exemplary references are made to Dingwall, and Laskey, Ann, Rev. Cell Biol., 2:367-390, 1986; Bonnerot, et al., Proc. Natl. Acad. Sci. USA, 84:6795-6799, 1987; Galileo, et al., Proc. Natl. Acad. Sci. USA, 87:458-462, 1990. Targeting groups for the hepatobiliary system may be selected, as suggested in U.S. Pat. Nos. 5,573,752 and 5,582,814.
In exemplary embodiments, the implant comprises absorptive agents, e.g. to remove compounds from body fluids. Suitable absorptive agents include chelating agents, such as penicillamine, methylene tetramine dihydrochloride, EDTA, DMSA or deferoxamine mesylate, any other appropriate chemical modification, antibodies, and micro beads or other materials containing cross linked reagents for absorption of drugs, toxins or other agents.
In some exemplary embodiments, biologically active agents are selected from cells, cell cultures, organized cell cultures, tissues, organs of desired species and non-human organisms.
In exemplary embodiments, the beneficial agents comprise metal based nano-particles that are selected from ferromagnetic or superparamagnetic metals or metal-alloys, either further modified by coating with silanes or any other suitable polymer or not modified, for interstitial hyperthermia or thermoablation.
In another exemplary embodiment, it can be desirable to coat the implant on the outer surface or inner surface with a coating to enhance engraftment or biocompatibility. Such coatings may comprise carbon coatings, metal carbides, metal nitrides, metal oxides e.g. diamond-like carbon or silicon carbide, or pure metal layers of e.g. titanium, using PVD, Sputter-, CVD or similar vapor deposition methods or ion implantation.
In further exemplary embodiments it is preferable to produce a porous coating onto at least one part of the exemplary implant in a further step, such as porous carbon coatings as described in International Publications WO 2004/101177, WO 2004/101017 or WO 2004/105826, or porous composite-coatings as described in International Application PCT/EP2006/063450, or porous metal-based coatings as described in International Publication WO 2006/097503, or any other suitable porous coating.
In further exemplary embodiments a sol/gel-based beneficial agent can be incorporated into the exemplary implant or a sol/gel-based coating that can be dissolvable in physiologic fluids may be applied to at least a part of the implant, as described, e.g. in International Publications WO 2006/077256 or WO 2006/082221.
In some exemplary embodiments, it can be desirable to combine two or more different functional modifications as described above to obtain a functional implant.
Exemplary Methods of Manufacturing
The exemplary implants can be manufactured in one seamless part or with seams from multiple parts. The exemplary implants may be manufactured using known implant manufacturing techniques. Particularly, appropriate manufacturing methods include, but are not limited to, laser cutting, chemical etching or stamping of tubes. Another preferable option is the manufacturing by laser cutting, chemically etching, and stamping flat sheets, rolling of the sheets and, as a further option, welding the sheets. Other appropriate manufacturing techniques include electrode discharge machining or molding the exemplary implant with the desired design. A further option is to weld individual sections together. Any other suitable implant manufacturing process may also be applied and used.
Further exemplary methods for manufacturing the exemplary implant may be provided which can use a semi-finished part or the net-shaped part which provides a structural implant body material that can be carbonized appropriately. Such manufacturing methods for producing inorganic carbon material shapes are described in, e.g., International Publication WO2005/021462, exemplary methods for introducing porosity into carbon materials produced by carbonization of organic polymer precursors.
One exemplary option for manufacturing, e.g., stents can be to use tubes or sheets. The tubes or sheets comprises a chemically or physically connected phase of structural material as well as removable fillers, preferably fibrous or spherical or any other regularly or irregularly shaped particles, that also can be chemically or physically connected. The removable fillers are referred to as a template for generating the porous compartment or respective reservoir. Removal of templates results in formation of the porous compartment within the implant. Preferably the removable filler material will be removed by using appropriate solvents, particularly if the material is an organic compound, a salt or the like. Suitable exemplary solvents may be, for example, (hot) water, diluted or concentrated inorganic or organic acids, bases or organic solvents, and the like. Another exemplary method comprises a thermolytic degradation or vaporization of a filler or template material at elevated temperatures. The temperatures may be used in the range of about 100° C. to 1500° C., and preferably in the range of about 300° C. to 800° C. For example, the thermal degradation can occur after manufacturing the desired implant design using, e.g., tubes or sheets.
An exemplary method for manufacturing the implantable device of the present invention can include the structuring of a precursor material, e.g., a polymer, a phenolic resin, mesophase pitch, tar, or the like, into a net-shape of the implant supporting structure and subsequent treatment thereof at elevated temperatures to convert the precursor material into an inorganic carbon material as described above. Non-carbon material additives to produce composites and/or removable fillers or templates for generating pores may be added to the precursor materials as desired before the high temperature treatment. Precursor materials may be structured to a mixture of structural materials and template materials of the desired implant design in a suitable way by folding, embossing, punching, pressing, extruding, gathering, injection molding, or any other conventional technique. In this exemplary manney, certain implant structures of a regular or irregular type can be provided as a net shape precursor of the implants according to this invention, which are subsequently converted to the inorganic carbon implants of the invention at elevated temperatures. Other known methods of structuring may include, e.g., wet or dry spinning methods, electro-spinning and the like, or knitting, weaving and any other known method to produce woven or non-woven articles or forms of regular or irregular forms.
Another exemplary method can be used to provide first an organic precursor material that can be shaped into sheets or tubes, optionally with multiple layers, or molded into semi-finished parts or the final shape of the desired implant.
Organic or polymeric precursor materials for producing the inorganic carbon material of the implant by high temperature treatment, such as carbonization can include homopolymers, copolymers prepolymeric forms and/or oligomers of aliphatic or aromatic polyolefines, such as polyethylene, polypropylene, polybutene, polyisobutene, polypentene; polybutadiene; polyvinyls, such as polyvinyl chloride, polyvinylacetate, or polyvinyl alcohol, polyacrylates, such as poly(meth)acrylic acid, polymethylmethacrylate (PMMA), polyacrylocyano acrylate; polyacrylonitril, polyamide, polyester, polyurethane, polystyrene, polytetrafluoroethylene; polyethylene vinyl acetate, silicones; poly(ester urethanes), poly(ether urethanes), poly(ester ureas), polyethers, such as polyethylene oxide, polypropylene oxide, pluronics, polytetramethylene glycol; polyvinylpyrrolidone, poly(vinyl acetate phthalate), or shellac, and combinations of these.
In further exemplary embodiments, the polymer for producing the implant of inorganic carbon material can include unsaturated or saturated polyesters, alkyd resins, epoxy-polymers, epoxy resins, phenoxy resins, nylon, polyimide, polyetherimide, polyamideimide, polyesterimide, polyesteramideimide, polyurethane, polycarbonate, polystyrene, polyphenol, polyvinylester, polysilicon, polyacetal, cellulose acetate, polysulfone, polyphenylsulfone, polyethersulfone, polyketone, polyetherketone, polyetheretherketone, polyetherketonketones, polybenzimidazole, polybenzoxazole, polybenzthiazole, polyfluorocarbons, polyphenylenether, polyarylate, cyanatoester-polymers, copolymers or mixtures of any of these.
Suitable polyacrylates may further comprise aliphatic unsaturated organic compounds, e.g. polyacrylamide and unsaturated polyesters from condensation reactions of unsaturated dicarboxylic acids and diols, as well as vinyl-derivatives, or compounds having terminal double bonds. Examples can include N-vinylpyrrollidone, styrene, vinyl-naphthalene or vinylphtalimide. Methacrylamid-derivatives include N-alkyl- or N-alkylen-substituted or unsubstituted (meth)acrylamide, such as acrylamid, methacrylamide, N-methacrylamide, N-methylmethacrylamide, N-ethylacrylamide, N,N-dimethylacrylamide, N,N-dimethylmethacrylamide, N,N-diethylacrylamide, N-ethylmethacrylamide, N-methyl-N-ethylacrylamide, N-isopropylacrylamide, N-n-propylacrylamide, N-isopropylmethacrylamide, N-n-propylmethacrylamide, N-acryloyloylpyrrolidine, N-methacryloylpyrrolidine, N-acryloylpiperidine, N-methacryloylpiperidine, N-acryloylhexahydroazepine, N-acryloylmorpholine or N-methacryloylmorpholine.
Further suitable exemplary polymers can include unsaturated and saturated polyesters, particularly also including alkyd resins. The polyesters may contain polymeric chains, a varying number of saturated or aromatic dibasic acids and anhydrides, or epoxy resins, which may be used as monomers, oligomers or polymers, optionally crosslinked as desired, can be selected, particularly those which comprise one or several oxirane rings, one aliphatic, aromatic or mixed aliphatic-aromatic molecular structural element, or exclusively non-benzoid structures, e.g., aliphatic or cycloaliphatic structures with or without substituents, such as halogen, ester groups, ether groups, sulfonate groups, siloxane groups, nitro groups, or phosphate groups, or any combination thereof.
In certain exemplary embodiments of the present invention, the precursor material may include epoxy resins, for example of the glycidyl-epoxy type, such as those equipped with the diglycidyl groups of bisphenol A. Further epoxy resins include amino derivatized epoxy resins, particularly tetraglycidyl diaminodiphenyl methane, triglycidyl-p-aminophenol, triglycidyl-m-maminophenole, or triglycidyl aminocresole and their isomers, phenol derivatized epoxy resins, such as, for example, epoxy resins of bisphenol A, bisphenol F, bisphenol S, phenol-novolac, cresole-novolac or resorcinole, phenoxy resins, as well as alicyclic epoxy resins. Furthermore, halogenated epoxy resins, glycidyl ethers of polyhydric phenols, diglycidylether of bisphenol A, glycidylethers of phenole-formaldehyde-novolac resins and resorcinole diglycidylether, as well as further epoxy resins as described in U.S. Pat. No. 3,018,262, herewith incorporated by reference, may be used. These exemplary materials may be easily structured, worked, and solidified or cured e.g. thermally or by radiation or cross linking, before being converted into the inorganic carbon material.
For example, in exemplary embodiments of the present invention, a stent may be produced from a suitable polymeric precursor material, such as one of those described herein, e.g., a phenol-formaldehyde novolac resin, which may optionally be mixed with a porogen (is porosity of the inorganic carbon material is desired). The porogen can be any material easily decomposable during carbonization, for example, polyethylene beads of a suitable size, such as about 100 μm size. A typical example for a suitable porogen may be polyethylene beads, such as “micro scrub”, commercially available from Micro Powders Inc. If no porosity is desired, the porogen can be left out. Alternatively, porosity may be produced by applying the precursor material onto a thermally decomposable template material such as polyethylene in such instance, pores can be produced during carbonization from the decomposition products of the template, which flow through the carbonizing polymeric precursor. To the precursor or its mixture with the porogen in a suitable ratio, such as 3:1 (wt/wt), optionally a cross-linker or other additives, such as hexamethylene tetramine in case of a phenolic resin used, can be added in a suitable amount, e.g., to obtain about 10% cross-linker content, and mixed, e.g., a conventional stirrer at about 20 rpm and filled into a mould, e.g., a metal mould. The mould comprising the precursors can then be cured or dried, whatever is necessary for the particular materials selected, for example by heating at about 150° C. for about 4 hours. The resulting hollow polymeric precursor shape. e.g., a hollow tube, such as a phenolic resin tube, can then subsequently conventionally be carbonized into the inorganic carbon material.
In an exemplary setup using phenolic resin and polyethylene beads, such precursor tube can have a wall thickness of about 4.5 mm, a length of about 81 cm and a lumen diameter of about 10.5 mm. Subsequently, this exemplary tube can be carbonized in a standard tube reactor at about 2000° C. in nitrogen atmosphere (flow rate of about 2000 ml/min) using a heating ramp of about 1K/min, the dwell time can be about 8 hours. During carbonization, the exemplary tube may be supported by a stainless steel spit. The resulting carbonized tube may be shrunk to about 0.5 mm wall thickness, an inner lumen diameter of about 1.5 mm and a length of about 65 cm.
The carbonized exemplary stent green bodies can then be patterned with any suitable conventional method as described above. In the exemplary setup described herein, a conventional laser cutting can be carried out by cutting a 3-D coronary stent pattern out of the tube. The surface of the carbon tube and respective stent may be matt, indicating porosity. A field emission scanning electron microscope at about 5,000× magnification may show a porous carbon with a pore size of approx. 1 μm.
It should be noted that the term ‘comprising’ does not exclude other elements or steps and the ‘a’ or ‘an’ does not exclude a plurality. In addition elements described in association with the different embodiments may be combined. It should be noted that the reference signs in the claims shall not be construed as limiting the scope of the claims.
Having thus described in detail several exemplary embodiments of the present invention, it is to be understood that the present invention described above is not to be limited to particular details set forth in the above description, as many apparent variations thereof are possible without departing from the spirit or scope of the present invention. The exemplary embodiments of the present invention are disclosed herein or are obvious from and encompassed by the detailed description. The detailed description, given by way of example, but not intended to limit the present invention solely to the specific embodiments described, may best be understood in conjunction with the accompanying Figures.
The foregoing applications, and all documents cited therein or during their prosecution (“appln. cited documents”) and all documents cited or referenced in the appln. cited documents, and all documents cited or referenced herein (“herein cited documents”), and all documents cited or referenced in the herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the present invention.
The present invention claims priority of U.S. provisional application Ser. No. 60/890,248 filed Feb. 16, 2007, the entire disclosure of which is incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| 60890248 | Feb 2007 | US |
